  | Grégoire, C., Baussard, L., Ernst, M., Diep, A. N., Faymonville, M.-E., DEVOS, M., Jerusalem, G.* , & Vanhaudenhuyse, A.*. (09 January 2024). Evaluation of a psychoneurological symptom cluster in patients with breast or digestive cancer: a longitudinal observational study. BMC Cancer, 24 (51). doi:10.1186/s12885-023-11799-x  Peer Reviewed verified by ORBi* These authors have contributed equally to this work. |
 | Nakamura, Y., Mizuno, N., Sunakawa, Y., Canon, J.-L., Galsky, M. D., Hamilton, E., Hayashi, H., Jerusalem, G., Kim, S. T., Lee, K.-W., Kankeu Fonkoua, L. A., Monk, B. J., Nguyen, D., Oh, D.-Y., Okines, A., O'Malley, D. M., Pohlmann, P., Reck, M., Shin, S. J., ... Bekaii-Saab, T. (20 December 2023). Tucatinib and Trastuzumab for Previously Treated Human Epidermal Growth Factor Receptor 2-Positive Metastatic Biliary Tract Cancer (SGNTUC-019): A Phase II Basket Study. Journal of Clinical Oncology, 41 (36), 5569 - 5578. doi:10.1200/JCO.23.00606 Peer Reviewed verified by ORBi |
 | Jerusalem, G., Prat, A., Salgado, R., Reinisch, M., Saura, C., Ruiz-Borrego, M., Nikolinakos, P., Ades, F., Filian, J., Huang, N., Mazzei-Abba, A., & Tolaney, S. M. (December 2023). Neoadjuvant nivolumab + palbociclib + anastrozole for oestrogen receptor-positive/human epidermal growth factor receptor 2-negative primary breast cancer: Results from CheckMate 7A8. Breast, 72, 103580. doi:10.1016/j.breast.2023.103580 Peer reviewed |
 | Goetz, M. P., Hamilton, E. P., Campone, M., Hurvitz, S. A., Cortes, J., Johnston, S., Llombart-Cussac, A., Kaufman, P. A., Toi, M., Jerusalem, G., Graham, H., Wang, H., Jansen, V. M., Litchfield, L. M., & Martín, M. (2023). Landscape of baseline and acquired genomic alterations in circulating tumor DNA with abemaciclib alone or with endocrine therapy in advanced breast cancer. Clinical Cancer Research. doi:10.1158/1078-0432.CCR-22-3573 Peer Reviewed verified by ORBi |
  | Grégoire, C., Faymonville, M.-E., Vanhaudenhuyse, A., Jerusalem, G., Monseur, J., & Bragard, I. (08 September 2023). A group intervention combining self-hypnosis and self-care in oncology: implementation in daily life and perceived usefulness. International Journal of Clinical and Experimental Hypnosis, 71 (3). Peer Reviewed verified by ORBi |
 | Marie, N.* , Grégoire, C.* , Sombrun, C., Faymonville, M.-E., Van Nitsen, V., De Ribaucourt, S., Jerusalem, G., Gosseries, O.* , & Vanhaudenhuyse, A.*. (04 September 2023). Self-induced cognitive trance, hypnosis and meditation to improve quality of life after cancer [Paper presentation]. GIGA Day, Liege, Belgium. * These authors have contributed equally to this work. |
 | Neven, P., Fasching, P. A., Chia, S., Jerusalem, G., De Laurentiis, M., Im, S.-A., Petrakova, K., Bianchi, G. V., Martín, M., Nusch, A., Sonke, G. S., De la Cruz-Merino, L., Beck, J. T., Zarate, J. P., Wang, Y., Chakravartty, A., Wang, C., & Slamon, D. J. (31 August 2023). Updated overall survival from the MONALEESA-3 trial in postmenopausal women with HR+/HER2- advanced breast cancer receiving first-line ribociclib plus fulvestrant. Breast Cancer Research, 25 (1), 103. doi:10.1186/s13058-023-01701-9 Peer Reviewed verified by ORBi |
 | Grégoire, C.* , Marie, N.* , Sombrun, C., Faymonville, M.-E., van Nitsen, V., de Ribaucourt, S., Jerusalem, G., Vanhaudenhuyse, A.* , & Gosseries, O.*. (06 July 2023). Auto-hypnose, méditation d’autocompassion et transe cognitive auto-induite pour améliorer la qualité de vie en oncologie [Paper presentation]. 12ème Congrès de l’Association Francophone de Psychologie de la Santé. Peer reviewed* These authors have contributed equally to this work. |
 | Depoorter, V., Vanschoenbeek, K., Decoster, L., Silversmit, G., Debruyne, P. R., De Groof, I., Bron, D., Cornélis, F., Luce, S., Focan, C., Verschaeve, V., Debugne, G., Langenaeken, C., Van Den Bulck, H., Goeminne, J.-C., Teurfs, W., Jerusalem, G., Schrijvers, D., Petit, B., ... Wildiers, H. (July 2023). Long-term health-care utilisation in older patients with cancer and the association with the Geriatric 8 screening tool: a retrospective analysis using linked clinical and population-based data in Belgium. The Lancet Healthy Longevity, 4 (7), 326 - e336. doi:10.1016/S2666-7568(23)00081-8 Peer Reviewed verified by ORBi |
 | Depoorter, V., Vanschoenbeek, K., Decoster, L., Silversmit, G., Debruyne, P. R., De Groof, I., Bron, D., Cornélis, F., Luce, S., Focan, C., Verschaeve, V., Debugne, G., Langenaeken, C., Van Den Bulck, H., Goeminne, J.-C., Teurfs, W., Jerusalem, G., Schrijvers, D., Petit, B., ... Wildiers, H. (26 June 2023). End-of-Life Care in the Last Three Months before Death in Older Patients with Cancer in Belgium: A Large Retrospective Cohort Study Using Data Linkage. Cancers, 15 (13). doi:10.3390/cancers15133349 Peer Reviewed verified by ORBi |
 | Grégoire, C.* , Marie, N.* , Sombrun, C., Faymonville, M.-E., van Nitsen, V., De Ribaucourt, S., Jerusalem, G., Vanhaudenhuyse, A.* , & Gosseries, O.*. (04 May 2023). Impact de l’auto-hypnose, la méditation d’autocompassion et la transe cognitive auto-induite sur la qualité de vie et la neurophysiologie de patients en oncologie [Paper presentation]. 1 er Congrès de recherche sur la Transe Cognitive Auto-Induite, Lyon, France. Peer reviewed* These authors have contributed equally to this work. |
| Grégoire, C.* , Marie, N.* , Sombrun, C., Faymonville, M.-E., van Nitsen, V., de Ribaucourt, S., Jerusalem, G., Vanhaudenhuyse, A.* , & Gosseries, O.*. (22 April 2023). Hypnosis, mindful self-compassion meditation, and self-induced cognitive trance to improve pain in post-treatment patients with cancer [Poster presentation]. 2nd Belgian Pain Society Young Researchers Day, Ghent, Belgium. Peer reviewed* These authors have contributed equally to this work. |
Marie, N.* , Grégoire, C.* , Sombrun, C., Faymonville, M.-E., Van Nitsen, V., De Ribaucourt, S., Jerusalem, G., Vanhaudenhuyse, A.* , & Gosseries, O.*. (16 April 2023). La transe cognitive auto-induite : Etat des lieux et exemples d’applications cliniques [Paper presentation]. 22e Forum des Sciences Cognitives : Cognition et états de conscience modifiés, Paris, France. Editorial reviewed* These authors have contributed equally to this work. |
 | Burniat, A., Noël, A., Colige, A., Vanderplasschen, A., de Kerchove d'Exaerde, A., Kupper Cardozo, A., Van Keymeulen, A., Moens, A., Bondue, A., Herpain, A., Marchant, A., Loumaye, A., Beck, B., Van den Heyden, B., Corvilain, B., Lakaye, B., Rogister, B., Malgrange, B., Michiels, C., ... Brunko, E. (2023). Cent scientifiques répliquent à SEA (Suppression des Expériences sur l’Animal vivant) et dénoncent sa désinformation. La Libre Belgique. |
 | Poulet, C.* , Debit, A.* , Josse, C., Jerusalem, G., Azencott, C.-A., Bours, V., & Van Steen, K. (2023). Assessing Random Forest self-reproducibility for optimal short biomarker signature discovery. ORBi-University of Liège. https://orbi.uliege.be/handle/2268/303314. doi:10.1101/2023.03.29.534695 * These authors have contributed equally to this work. |
 | Depoorter, V., Vanschoenbeek, K., Decoster, L., De Schutter, H., Debruyne, P. R., De Groof, I., Bron, D., Cornélis, F., Luce, S., Focan, C., Verschaeve, V., Debugne, G., Langenaeken, C., Van Den Bulck, H., Goeminne, J.-C., Teurfs, W., Jerusalem, G., Schrijvers, D., Petit, B., ... Wildiers, H. (March 2023). Linking clinical and population-based data in older patients with cancer in Belgium: Feasibility and clinical outcomes. Journal of Geriatric Oncology, 14 (2), 101428. doi:10.1016/j.jgo.2023.101428 Peer Reviewed verified by ORBi |
 | de Azambuja, E., Agostinetto, E., Procter, M., Eiger, D., Pondé, N., Guillaume, S., Parlier, D., Lambertini, M., Desmet, A., Caballero, C., Aguila, C., Jerusalem, G., Walshe, J. M., Frank, E., Bines, J., Loibl, S., Piccart-Gebhart, M., Ewer, M. S., Dent, S., ... APHINITY Steering Committee and Investigators. (February 2023). Cardiac safety of dual anti-HER2 blockade with pertuzumab plus trastuzumab in early HER2-positive breast cancer in the APHINITY trial. ESMO Open, 8 (1), 100772. doi:10.1016/j.esmoop.2022.100772 Peer Reviewed verified by ORBi |
 | Li, J., Zhang, D., Liu, Z., Wang, Y., Li, X., Wang, Z., Liang, G., Yuan, X., Li, Y., Komorowski, A. L., Rozen, W. M., Orlandi, A., Takabe, K., Franceschini, G., Jerusalem, G., & Wang, X. (31 January 2023). The combined effect and mechanism of antiangiogenic drugs and PD-L1 inhibitor on cell apoptosis in triple negative breast cancer. Annals of Translational Medicine, 11 (2), 83. doi:10.21037/atm-22-6446 Peer Reviewed verified by ORBi |
 | Barlesi, F., Isambert, N., Felip, E., Cho, B. C., Lee, D. H., Peguero, J., Jerusalem, G., Penel, N., Saada-Bouzid, E., Garrido, P., Helwig, C., Locke, G., Ojalvo, L. S., & Gulley, J. L. (2023). Bintrafusp Alfa, a Bifunctional Fusion Protein Targeting TGF-β and PD-L1, in Patients With Non-Small Cell Lung Cancer Resistant or Refractory to Immune Checkpoint Inhibitors. Oncologist. doi:10.1093/oncolo/oyac253 Peer Reviewed verified by ORBi |
 | Corona, S. P., Giudici, F., Jerusalem, G., Ciruelos, E., Strina, C., Sirico, M., Bernocchi, O., Milani, M., Dester, M., Ziglioli, N., Barbieri, G., Cervoni, V., Montemurro, F., & Generali, D. (06 December 2022). Addendum: Impact of BMI on the outcome of metastatic breast cancer patients treated with everolimus: a retrospective exploratory analysis of the BALLET study. Oncotarget, 13 (1), 1307. doi:10.18632/oncotarget.28317 Peer Reviewed verified by ORBi |
 | Jerusalem, G., Park, Y. H., Yamashita, T., Hurvitz, S. A., Modi, S., Andre, F., Krop, I. E., Gonzàlez Farré, X., You, B., Saura, C., Kim, S.-B., Osborne, C. R., Murthy, R. K., Gianni, L., Takano, T., Liu, Y., Cathcart, J., Lee, C., & Perrin, C. (02 December 2022). Trastuzumab Deruxtecan in HER2-Positive Metastatic Breast Cancer Patients with Brain Metastases: A DESTINY-Breast01 Subgroup Analysis. Cancer Discovery, 12 (12), 2754 - 2762. doi:10.1158/2159-8290.CD-22-0837 Peer Reviewed verified by ORBi |
 | Schettini, F., Venturini, S., Giuliano, M., Lambertini, M., Pinato, D. J., Onesti, C. E., De Placido, P., Harbeck, N., Lüftner, D., Denys, H., Van Dam, P., Arpino, G., Zaman, K., Mustacchi, G., Gligorov, J., Awada, A., Campone, M., Wildiers, H., Gennari, A., ... Generali, D. (December 2022). Multiple Bayesian network meta-analyses to establish therapeutic algorithms for metastatic triple negative breast cancer. Cancer Treatment Reviews, 111, 102468. doi:10.1016/j.ctrv.2022.102468 Peer Reviewed verified by ORBi |
 | Troisfontaine, F., Denis, C., Servais, S., Lousberg, L., & Jerusalem, G. (December 2022). Les CAR-T cells dans le traitement des tumeurs solides : où en sommes-nous ? Revue Médicale de Liège, 77 (12), 706 - 709. Editorial Reviewed verified by ORBi |
 | Kenis, C., Decoster, L., Flamaing, J., Debruyne, P. R., De Groof, I., Focan, C., Cornélis, F., Verschaeve, V., Bachmann, C., Bron, D., Van den Bulck, H., Schrijvers, D., Langenaeken, C., Specenier, P., Jerusalem, G., Praet, J.-P., De Cock, J., Lobelle, J.-P., Wildiers, H., & Milisen, K. (19 November 2022). Incidence of falls and fall-related injuries and their predictive factors in frail older persons with cancer: a multicenter study. BMC Geriatrics, 22 (1), 877. doi:10.1186/s12877-022-03574-7 Peer Reviewed verified by ORBi |
 | Niu, N., Qiu, F., Xu, Q., He, G., Gu, X., Guo, W., Zhang, D., Li, Z., Zhao, Y., Li, Y., Li, K., Zhang, H., Zhang, P., Huang, Y., Zhang, G., Han, H., Cai, Z., Li, P., Xu, H., ... Liu, C. (17 November 2022). A multicentre single arm phase 2 trial of neoadjuvant pyrotinib and letrozole plus dalpiciclib for triple-positive breast cancer. Nature Communications, 13 (1), 7043. doi:10.1038/s41467-022-34838-w Peer Reviewed verified by ORBi |
 | Rugo, H. S., Kabos, P., Beck, J. T., Jerusalem, G., Wildiers, H., Sevillano, E., Paz-Ares, L., Chisamore, M. J., Chapman, S. C., Hossain, A. M., Chen, Y., & Tolaney, S. M. (05 November 2022). Abemaciclib in combination with pembrolizumab for HR+, HER2- metastatic breast cancer: Phase 1b study. npj Breast Cancer, 8 (1), 118. doi:10.1038/s41523-022-00482-2 Peer Reviewed verified by ORBi |
 | Meert, G., Kenis, C., Milisen, K., Debruyne, P. R., De Groof, I., Focan, C., Cornélis, F., Verschaeve, V., Bachmann, C., Bron, D., Den Bulck, H. V., Schrijvers, D., Langenaeken, C., Specenier, P., Jerusalem, G., Praet, J.-P., Lobelle, J.-P., Flamaing, J., Wildiers, H., & Decoster, L. (November 2022). Functional status in older patients with cancer and a frailty risk profile: A multicenter observational study. Journal of Geriatric Oncology, 13 (8), 1162 - 1171. doi:10.1016/j.jgo.2022.08.019 Peer Reviewed verified by ORBi |
 | Marie, N.* , Grégoire, C.* , Sombrun, C., Faymonville, M.-E., Kotsou, I., van Nitsen, V., de Ribaucourt, S., Jerusalem, G., Laureys, S., Gosseries, O.* , & Vanhaudenhuyse, A.*. (14 October 2022). Hypnose, méditation et transe cognitive auto-induite pour améliorer la qualité de vie des patients oncologiques après le traitement [Paper presentation]. Congrès international "Comprendre les processus de changement: Apports des méthodes qualitatives et mixtes", Liège, Belgium. Peer reviewed* These authors have contributed equally to this work. |
 | Grégoire, C.* , Marie, N.* , Sombrun, C., Faymonville, M.-E., Kotsou, I., van Nitsen, V., de Ribaucourt, S., Jerusalem, G., Laureys, S., Gosseries, O.* , & Vanhaudenhuyse, A.*. (08 October 2022). Impact de l’auto-hypnose, la méditation et la transe cognitive auto-induite chez des patients en oncologie : protocole d’étude [Paper presentation]. Colloque International : La recherche en psychothérapie : évaluation ou dévaluation ?, Paris, France. Peer reviewed* These authors have contributed equally to this work. |
 | Gennigens, C., Jerusalem, G., LAPAILLE, L., De Cuypere, M., Streel, S., Kridelka, F., & Ray-Coquard, I. (09 September 2022). Recurrent or primary metastatic cervical cancer: current and future treatments. ESMO Open, 7 (5), 1-3. doi:10.1016/j.esmoop.2022.100579 Peer Reviewed verified by ORBi |
| Grégoire, C.* , Marie, N.* , Corine, S., Faymonville, M.-E., Valérie van Nitsen, Sybille de Ribaucourt, Jerusalem, G., Laureys, S., Vanhaudenhuyse, A.* , & Gosseries, O.*. (06 September 2022). Hypnosis, meditation, and self-induced cognitive trance to improve post-treatment oncological patients’ quality of life [Poster presentation]. GIGA Day 2022, Liège, Belgium. * These authors have contributed equally to this work. |
 | Hamilton, E., Cortes, J., Ozyilkan, O., Chen, S.-C., Petrakova, K., Manikhas, A., Jerusalem, G., Hegg, R., Huober, J., Zhang, W., Chen, Y., & Martin, M. (August 2022). nextMONARCH Phase 2 randomized clinical trial: overall survival analysis of abemaciclib monotherapy or in combination with tamoxifen in patients with endocrine-refractory HR + , HER2- metastatic breast cancer. Breast Cancer Research and Treatment, 195 (1), 55 - 64. doi:10.1007/s10549-022-06662-9 Peer Reviewed verified by ORBi |
 | Marie, N.* , Grégoire, C.* , Sombrun, C., Faymonville, M.-E., Kotsou, I., van Nitsen, V., de Ribaucourt, S., Jerusalem, G., Laureys, S., Vanhaudenhuyse, A.* , & Gosseries, O.*. (15 July 2022). Phenomenological experience and clinical benefits of hypnosis and cognitive trance [Poster presentation]. Association for the Scientific Study of Consciousness 25 Amsterdam, Amsterdam, Netherlands. Peer reviewed* These authors have contributed equally to this work. |
 | Grégoire, C., FAYMONVILLE, M.-E., JERUSALEM, G., Gosseries, O., & VANHAUDENHUYSE, A. (23 June 2022). Psycho-oncology interventions focusing on fatigue and sleep disturbances. Current Opinion in Oncology, 34 (4), 270-278. doi:10.1097/CCO.0000000000000847 Peer Reviewed verified by ORBi |
Pottier, C., Montero-Ruiz, L., Noël, A., Jerusalem, G., & Sounni, N. E. (June 2022). Non genetic mechanisms of ER+ HER2- breast cancer resistance to the combination of Palbociclib and Fulvestrant [Poster presentation]. The European Association for Cancer Research Congress, Seville, Spain. Editorial reviewed |
 | SIBILLE, A., CORHAY, J.-L., LOUIS, R., Ninane, V., JERUSALEM, G.* , & DUYSINX, B.*. (03 May 2022). Eosinophils and Lung Cancer: From Bench to Bedside. International Journal of Molecular Sciences, 23 (9), 5066. doi:10.3390/ijms23095066 Peer Reviewed verified by ORBi* These authors have contributed equally to this work. |
 | Kirkove, D.* , STREEL, S.* , ORY, A., AUBOUY, G., DE JODE, E., JERUSALEM, G., GAGNAYRE, R., & Pétré, B. (May 2022). Immuno’Act - J’agis sur les effets secondaires liés à mon immunothérapie oncologique [Poster presentation]. Congrès Éducation Thérapeutique du Patient 2022, Montpellier, France. Editorial reviewed* These authors have contributed equally to this work. |
 | Scheen, A., Noël, A., Delvenne, P., & Jerusalem, G. (May 2022). Inflammation et cancer : une relation complexe à double sens. Revue Médicale de Liège, 77 (5-6), 354-360. Editorial Reviewed verified by ORBi |
Grégoire, C.* , VANHAUDENHUYSE, A.* , Marie, N., Sombrun, C., FAYMONVILLE, M.-E., Kotsou, I., van Nitsen, V., de Ribaucourt, S., JERUSALEM, G., LAUREYS, S., & Gosseries, O. (May 2022). Impact de l’auto-hypnose, la méditation et la transe cognitive auto-induite chez des patients en oncologie : protocole d’étude [Paper presentation]. 12e forum de la Confédération Francophone d'Hypnose et Thérapies Brèves (CFHTB), Luxembourg, Luxembourg. Peer reviewed* These authors have contributed equally to this work. |
 | Marie, N., Grégoire, C., Sombrun, C., Faymonville, M.-E., Kotsou, I., Van Nitsen, V., De Ribaucourt, S., Jerusalem, G., Laureys, S., Vanhaudenhuyse, A., & Gosseries, O. (22 March 2022). Hypnose, méditation et transe cognitive auto-induite en oncologie : impact sur la qualité de vie et la neurophysiologie [Paper presentation]. Beating Cancer Together Ceremony, Bruxelles, Belgium. |
 | PAYE, A., Truong, A., Yip, C., Cimino, J., Blacher, S., Munaut, C., Cataldo, D., Foidart, J. M., Maquoi, E., Collignon, J., Delvenne, P., Jerusalem, G., Noël, A., & Sounni, N. E. (15 February 2022). Editor's Note: EGFR Activation and Signaling in Cancer Cells Are Enhanced by the Membrane-Bound Metalloprotease MT4-MMP. Cancer Research, 82 (4), 734. doi:10.1158/0008-5472.CAN-21-4292 Peer Reviewed verified by ORBi |
 | Malorni, L., Tyekucheva, S., Hilbers, F. S., Ignatiadis, M., Neven, P., Colleoni, M., Henry, S., Ballestrero, A., Bonetti, A., JERUSALEM, G., Papadimitriou, K., Bernardo, A., Seles, E., Duhoux, F. P., MacPherson, I. R., Thomson, A., Davies, D. M., Bergqvist, M., Migliaccio, I., ... Breast International Group and PYTHIA Collaborators. (13 February 2022). Serum thymidine kinase activity in patients with hormone receptor-positive and HER2-negative metastatic breast cancer treated with palbociclib and fulvestrant. European Journal of Cancer, 164, 39-51. doi:10.1016/j.ejca.2021.12.030 Peer Reviewed verified by ORBi |
 | Grégoire, C., Marie, N., Sombrun, C., FAYMONVILLE, M.-E., Kotsou, I., Van Nitsen, V., De Ribaucourt, S., JERUSALEM, G., LAUREYS, S., VANHAUDENHUYSE, A.* , & Gosseries, O.*. (2022). Hypnosis, meditation and self-induced cognitive trance to improve post-treatment oncological patients’ quality of life: study protocol. Frontiers in Psychology. doi:10.3389/fpsyg.2022.807741 Peer Reviewed verified by ORBi* These authors have contributed equally to this work. |
 | Coibion, M.* , OLIVIER, F.* , Courtois, A., MAES, N., Jossa, V.* , & JERUSALEM, G.*. (10 February 2022). A Randomized Prospective Non-Inferiority Trial of Sentinel Lymph Node Biopsy in Early Breast Cancer: Blue Dye Compared with Indocyanine Green Fluorescence Tracer. Cancers, 14 (4), 888. doi:10.3390/cancers14040888 Peer Reviewed verified by ORBi* These authors have contributed equally to this work. |
 | Moonen, D., Jacquemart, C., Jerusalem, G., & Lancellotti, P. (February 2022). Late cardiovascular side effects of cancer treatment. Belgian Journal of Medical Oncology, 16 (1), 11-16. Peer Reviewed verified by ORBi |
 | JERUSALEM, G., Delea, T. E., Martin, M., De Laurentiis, M., Nusch, A., Beck, J. T., Chan, A., Im, S.-A., Neven, P., Lonshteyn, A., Chandiwana, D., Lanoue, B., & Fasching, P. A. (13 January 2022). Quality-Adjusted Survival with Ribociclib Plus Fulvestrant Versus Placebo Plus Fulvestrant in Postmenopausal Women with HR±HER2-Advanced Breast Cancer in the Monaleesa-3 Trial. Clinical Breast Cancer, 22 (4), 326-335. doi:10.1016/j.clbc.2021.12.008 Peer Reviewed verified by ORBi |
 | Bartsch, R., Kolberg-Liedtke, C., JERUSALEM, G., Palmieri, C., & Janni, W. (04 January 2022). Expert Discussion: SABCS 2021. Breast Care, 17 (1), 101-106. doi:10.1159/000521762 Peer Reviewed verified by ORBi |
 | Grégoire, C., FAYMONVILLE, M.-E., VANHAUDENHUYSE, A., JERUSALEM, G., Willems, S., & Bragard, I. (2022). Randomized-controlled trial of an intervention combining self-care and self-hypnosis on fatigue, sleep and emotional distress in post-treatment cancer patients: 1-year follow up. International Journal of Clinical and Experimental Hypnosis, 70 (2), 136-155. doi:10.1080/00207144.2022.2049973 Peer Reviewed verified by ORBi |
 | ONESTI, C. E., Schroeder, H., Rorive, A., Sautois, B., Lecocq, M., Goffin, M., Gonne, E., Collinge, A., Nicolaers, L., Wéra, O., Catot, A., Loly, C., Paulus, A., Sibille, A., Lousberg, L., Troisfontaine, F., Collignon, J., Gennigens, C., Frères, P., ... Jerusalem, G. (2021). Oncological patients' reactions to COVID-19 pandemic: A single institution prospective study. Cancer Reports, 1571. doi:10.1002/cnr2.1571 Peer reviewed |
 | Slamon, D. J., Neven, P., Chia, S., Jerusalem, G., De Laurentiis, M., Im, S., Petrakova, K., Valeria Bianchi, G., Martín, M., Nusch, A., Sonke, G. S., De la Cruz-Merino, L., Beck, J. T., Ji, Y., Wang, C., Deore, U., Chakravartty, A., Zarate, J. P., Taran, T., & Fasching, P. A. (October 2021). Corrigendum to 'Ribociclib plus fulvestrant for postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer in the phase III randomized MONALEESA-3 trial: updated overall survival': [Annals of Oncology Volume 32, Issue 8, August 2021, Pages 1015-1024]. Annals of Oncology, 32 (10), 1307. doi:10.1016/j.annonc.2021.07.011 Peer Reviewed verified by ORBi |
 | OLIVIER, F.* , Courtois, A.* , Jossa, V., Bruck, G., Aouachria, S., Coibion, M.* , & JERUSALEM, G.*. (September 2021). Sentinel lymph node mapping with patent blue dye in patients with breast cancer: a retrospective single institution study. Gland Surgery, 10 (9), 2600-2607. doi:10.21037/gs-21-415 Peer Reviewed verified by ORBi* These authors have contributed equally to this work. |
 | JERUSALEM, G., Farah, S., Courtois, A., Chirgwin, J., Aebi, S., Karlsson, P., Neven, P., Hitre, E., Graas, M. P., Simoncini, E., Abdi, E., Kamby, C., Thompson, A., Loibl, S., Gavilá, J., Kuroi, K., Marth, C., Müller, B., O'Reilly, S., ... SOLE Investigators. (10 August 2021). Continuous versus intermittent extended adjuvant letrozole for breast cancer: final results of randomized phase III SOLE (Study of Letrozole Extension) and SOLE Estrogen Substudy. Annals of Oncology, 32 (10), 1256-1266. doi:10.1016/j.annonc.2021.07.017 Peer Reviewed verified by ORBi* These authors have contributed equally to this work. |
 | Poncin, A., Onesti, C. E., JOSSE, C., Boulet, D., Thiry, J., Bours, V., & Jerusalem, G. (August 2021). Immunity and Breast Cancer: Focus on Eosinophils. Biomedicines, 9 (9), 1087. doi:10.3390/biomedicines9091087 Peer Reviewed verified by ORBi |
| Grégoire, C., FAYMONVILLE, M.-E., VANHAUDENHUYSE, A., JERUSALEM, G., Willems, S., & Bragard, I. (07 July 2021). Effets d’une intervention basée sur l’hypnose sur la fatigue, le sommeil et la détresse de patients oncologiques [Paper presentation]. 11ème Congrès de l’Association Francophone de Psychologie de la Santé. Peer reviewed |
 | Slamon, D. J., Neven, P., Chia, S., JERUSALEM, G., De Laurentiis, M., Im, S., Petrakova, K., Valeria Bianchi, G., Martín, M., Nusch, A., Sonke, G. S., De la Cruz-Merino, L., Beck, J. T., Ji, Y., Wang, C., Deore, U., Chakravartty, A., Zarate, J. P., Taran, T., & Fasching, P. A. (05 June 2021). Ribociclib plus fulvestrant for postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer in the phase III randomized MONALEESA-3 trial: updated overall survival. Annals of Oncology, 32 (8), 1015-1024. doi:10.1016/j.annonc.2021.05.353 Peer Reviewed verified by ORBi |
 | Uyisenga, J. P.* , Debit, A.* , Poulet, C., Frères, P., Poncin, A., Thiry, J., Mutesa, L., Jerusalem, G., Bours, V.* , & JOSSE, C.*. (03 June 2021). Differences in plasma microRNA content impair microRNA-based signature for breast cancer diagnosis in cohorts recruited from heterogeneous environmental sites. Scientific Reports, 11 (1), 11698. doi:10.1038/s41598-021-91278-0 Peer Reviewed verified by ORBi* These authors have contributed equally to this work. |
 | Piccart, M., Procter, M., Fumagalli, D., de Azambuja, E., Clark, E., Ewer, M. S., Restuccia, E., Jerusalem, G., Dent, S., Reaby, L., Bonnefoi, H., Krop, I., Liu, T.-W., Pieńkowski, T., Toi, M., Wilcken, N., Andersson, M., Im, Y.-H., Tseng, L. M., ... Thomssen, C. (29 April 2021). Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer in the APHINITY Trial: 6 Years' Follow-Up. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 39 (13), 1448-1457. doi:10.1200/JCO.20.01204 Peer reviewed |
 | Grégoire, C., Marie, N., Sombrun, C., FAYMONVILLE, M.-E., Kotsou, I., van Nitsen, V., de Ribaucourt, S., JERUSALEM, G., LAUREYS, S., VANHAUDENHUYSE, A.* , & Gosseries, O.*. (02 March 2021). Hypnosis, cognitive trance and meditation on cancer patients: impact on quality of life and neurophysiology [Paper presentation]. GIGA-Consciousness Seminar. * These authors have contributed equally to this work. |
 | GREGOIRE, C., FAYMONVILLE, M.-E., VANHAUDENHUYSE, A., Charland-Verville, V., JERUSALEM, G., Willems, S., & Bragard, I. (11 February 2021). Exploratory controlled study of the impact of a hypnosis-based intervention on the couple’s communication and coping in the context of cancer. International Journal of Clinical and Experimental Hypnosis, 69 (2), 261-276. doi:10.1080/00207144.2021.1878897 Peer Reviewed verified by ORBi |
 | GREGOIRE, C., FAYMONVILLE, M.-E., VANHAUDENHUYSE, A., JERUSALEM, G., Willems, S., & Bragard, I. (February 2021). Randomized-controlled trial of a group intervention combining self-hypnosis and self-care: secondary results on self-esteem, emotional distress and regulation, and mindfulness in post-treatment cancer patients. Quality of Life Research, 30, 425-436. doi:10.1007/s11136-020-02655-7 Peer Reviewed verified by ORBi |
 | Pilard, C.* , Ancion, M.* , Delvenne, P., JERUSALEM, G., Hubert, P., & Herfs, M. (2021). Cancer immunotherapy: it’s time to better predict patients’ response. British Journal of Cancer, 125(7), 927-938. doi:10.1038/s41416-021-01413-x Peer Reviewed verified by ORBi* These authors have contributed equally to this work. |
 | SCHEEN, A., BEGUIN, Y., & JERUSALEM, G. (2021). L’oncologie, à un tournant de son histoire. Revue Médicale de Liège, 76, 297-299. Peer reviewed |
 | Chiavarina, B., Costanza, B., Ronca, R., Blomme, A., Rezzola, S., Chiodelli, P., Giguelay, A., Belthier, G., Doumont, G., Van Simaeys, G., Lacroix, S., Yokobori, T., Erkhem-Ochir, B., Balaguer, P., Cavailles, V., Fabbrizio, E., Di Valentin, E., Gofflot, S., Detry, O., ... Turtoi, A. (January 2021). Metastatic colorectal cancer cells maintain the TGFβ program and use TGFBI to fuel angiogenesis. Theranostics, 11 (4), 1626-1640. doi:10.7150/thno.51507 Peer Reviewed verified by ORBi |
 | Jossa, V., Olivier, F., LIFRANGE, E., Crevecoeur, A., COURTOIS, A., Coibion, M., & JERUSALEM, G. (2021). From modified radical mastectomy to infra-radical mastectomy: A phase I study for surgical de-escalation focusing on pathological analyses. Gland Surgery. doi:10.21037/gs-21-48 Peer Reviewed verified by ORBi |
 | GENNIGENS, C., DE CUYPERE, M., HERMESSE, J., KRIDELKA, F., & JERUSALEM, G. (2021). Optimal treatment in locally advanced cervical cancer. Expert Review of Anticancer Therapy, 657-671. doi:10.1080/14737140.2021.1879646 Peer Reviewed verified by ORBi |
 | Onesti, C. E., & Jerusalem, G. (2021). CDK4/6 inhibitors in breast cancer: differences in toxicity profiles and impact on agent choice. A systematic review and meta-analysis. Expert Review of Anticancer Therapy, 21 (3), 283-298. doi:10.1080/14737140.2021.1852934 Peer Reviewed verified by ORBi |
 | Lodewijckx, E., Kenis, C., Flamaing, J., Debruyne, P., De Groof, I., Focan, C., Cornélis, F., Verschaeve, V., Bachmann, C., Bron, D., Luce, S., Debugne, G., Van den Bulck, H., Goeminne, J.-C., Schrijvers, D., Geboers, K., Petit, B., Langenaeken, C., Van Rijswijk, R., ... Decoster, L. (2021). Unplanned hospitalizations in older patients with cancer: Occurrence and predictive factors. Journal of Geriatric Oncology, 12 (3), 368-374. doi:10.1016/j.jgo.2020.11.004 Peer Reviewed verified by ORBi |
 | Neven, P., Sonke, G. S., & Jerusalem, G. (2021). Ribociclib plus fulvestrant in the treatment of breast cancer. Expert Review of Anticancer Therapy, 1-14. doi:10.1080/14737140.2021.1840360 Peer Reviewed verified by ORBi |
 | Schettini, F., Giuliano, M., Lambertini, M., Bartsch, R., Pinato, D. J., ONESTI, C. E., Harbeck, N., Rottey, S., Van Dam, P. A., Zaman, K., Mustacchi, G., Gligorov, J., Awada, A., Campone, M., Wildiers, H., Gennari, A., Tjan-Heijnen, V. C. G., Cortes, J., Locci, M., ... Generali, D. (2021). Anthracyclines Strike Back: Rediscovering Non-Pegylated Liposomal Doxorubicin in Current Therapeutic Scenarios of Breast Cancer. Cancers, 13 (17), 4421. doi:10.3390/cancers13174421 Peer reviewed |
 | ONESTI, C. E., Tagliamento, M., Curigliano, G., Harbeck, N., Bartsch, R., Wildiers, H., Tjan-Heijnen, V., Martin, M., Rottey, S., Generali, D., Campone, M., Cristofanilli, M., Pusztai, L., Peeters, M., Berchem, G., Cortes, J., Ruhstaller, T., Ciruelos, E., Rugo, H. S., & Jerusalem, G. (2021). Expected Medium- and Long-Term Impact of the COVID-19 Outbreak in Oncology. JCO global oncology, 7, 162-172. doi:10.1200/GO.20.00589 Peer Reviewed verified by ORBi |
 | Schettini, F., Giuliano, M., Giudici, F., Conte, B., De Placido, P., Venturini, S., Rognoni, C., Di Leo, A., Locci, M., Jerusalem, G., Del Mastro, L., Puglisi, F., Conte, P., De Laurentiis, M., Pusztai, L., Rinmawi, M. F., Schiff, R., Arpino, G., De Placido, S., ... Generali, D. (2021). Endocrine-Based Treatments in Clinically-Relevant Subgroups of Hormone Receptor-Positive/HER2-Negative Metastatic Breast Cancer: Systematic Review and Meta-Analysis. Cancers, 13 (6), 1458 (21. doi:10.3390/cancers13061458 Peer Reviewed verified by ORBi |
 | Schmid, P., Sablin, M.-P., Bergh, J., Im, S.-A., Lu, Y.-S., Martínez, N., Neven, P., Lee, K. S., Morales, S., Pérez-Fidalgo, J. A., Adamson, D., Gonçalves, A., Prat, A., Jerusalem, G., Schlieker, L., Espadero, R.-M., Bogenrieder, T., Huang, D. C.-L., Crown, J., & Cortés, J. (2021). A phase Ib/II study of xentuzumab, an IGF-neutralising antibody, combined with exemestane and everolimus in hormone receptor-positive, HER2-negative locally advanced/metastatic breast cancer. Breast cancer research : BCR, 23 (1), 8. doi:10.1186/s13058-020-01382-8 Peer reviewed |
 | Onesti, C. E., JOSSE, C., Boulet, D., Bours, V., & JERUSALEM, G. (2020). High plasmatic levels of IL-4 and IL- 13 are associated with recurrence and worse survival in breast cancer. Tumori Journal. Peer Reviewed verified by ORBi |
 | ONESTI, C. E., JOSSE, C., Beaumecker, B., Boulet, D., Thiry, J., BOURS, V., & JERUSALEM, G. (2020). The relative eosinophil count in breast cancer as an emerging prognostic biomarker. European Journal of Cancer. doi:10.1016/S0959-8049(20)30766-8 Peer reviewed |
 | Guerini-Rocco, E., Gray, K. P., Fumagalli, C., Reforgiato, M. R., Leone, I., Rafaniello Raviele, P., Munzone, E., Kammler, R., Neven, P., Hitre, E., Jerusalem, G., Simoncini, E. L., Gombos, A., Deleu, I., Karlsson, P., Aebi, S., Chirgwin, J., Di Lauro, V., Thompson, A. M., ... Colleoni, M. (2020). Genomic aberrations and late recurrence in postmenopausal women with hormone receptor-positive early breast cancer: Results from the SOLE Trial. Clinical cancer research : an official journal of the American Association for Cancer Research. doi:10.1158/1078-0432.CCR-20-0126 Peer reviewed |
 | JERUSALEM, G., ONESTI, C. E., Generali, D., Harbeck, N., Wildiers, H., Curigliano, G., Campone, M., Tjan-Heijnen, V., Martin, M., Cristofanilli, M., Pusztai, L., Bartsch, R., Peeters, M., Berchem, G., Tagliamento, M., Cortès, J., Ruhsthaller, T., Ciruelos, E., Rottey, S., & Rugo, H. (2020). Expected medium and long term impact of the COVID-19 outbreak in oncology. Annals of Oncology. Peer Reviewed verified by ORBi |
 | ONESTI, C. E., Rugo, H. S., Generali, D., Peeters, M., Zaman, K., Wildiers, H., Harbeck, N., Martin, M., Cristofanilli, M., Cortes, J., Tjan-Heijnen, V., Hurvitz, S. A., Berchem, G., Tagliamento, M., Campone, M., Bartsch, R., De Placido, S., Puglisi, F., Rottey, S., ... JERUSALEM, G. (August 2020). Oncological care organisation during COVID-19 outbreak. ESMO Open, 5. doi:10.1136/esmoopen-2020-000853 Peer Reviewed verified by ORBi |
 | GREGOIRE, C., FAYMONVILLE, M.-E., VANHAUDENHUYSE, A., Charland-Verville, V., JERUSALEM, G., Willems, S., & Bragard, I. (July 2020). Effects of an intervention combining self-care and self-hypnosis on fatigue and associated symptoms in post-treatment cancer patients: A randomized-controlled trial. Psycho-oncology, 29 (7), 1165-1173. doi:10.1002/pon.5395 Peer Reviewed verified by ORBi |
 | Quinten, C., Kenis, C., Decoster, L., Debruyne, P. R., De Groof, I., Focan, C., Cornelis, F., Verschaeve, V., Bachmann, C., Bron, D., Luce, S., Debugne, G., Van den Bulck, H., Goeminne, J.-C., Schrijvers, D., Geboers, K., Petit, B., Langenaeken, C., Van Rijswijk, R., ... Wildiers, H. (July 2020). The prognostic value of patient-reported Health-Related Quality of Life and Geriatric Assessment in predicting early death in 6769 older (≥70 years) patients with different cancer tumors. Journal of Geriatric Oncology, 11 (6), 926-936. doi:10.1016/j.jgo.2020.03.017 Peer Reviewed verified by ORBi |
 | Jouret, G., GONNE, E., QUATRESOOZ, P., REGINSTER, M.-A., COLLINS, P., LEBAS, E., JERUSALEM, G., & NIKKELS, A. (2020). Cutaneous Breast Cancer Metastases Successfully Treated Using an Oxygen Flow Assisted Topical Administration of Methotrexate (OFAMTX). Dermatology and Therapy. doi:10.1007/s13555-020-00393-9 Peer Reviewed verified by ORBi |
 | Schettini, F., Giudici, F., Giuliano, M., Cristofanilli, M., Arpino, G., Del Mastro, L., Puglisi, F., De Placido, S., Paris, I., De Placido, P., Venturini, S., De Laurentis, M., Conte, P., Juric, D., Llombart-Cussac, A., Pusztai, L., Prat, A., Jerusalem, G., Di Leo, A., & Generali, D. (2020). Overall survival of CDK4/6-inhibitors-based treatments in clinically relevant subgroups of metastatic breast cancer: systematic review and meta-analysis. Journal of the National Cancer Institute. doi:10.1093/jnci/djaa071 Peer Reviewed verified by ORBi |
 | POTTIER, C., Fresnais, M., Gilon, M., JERUSALEM, G., Longuespée, R.* , & Sounni, N. E.*. (2020). Tyrosine Kinase Inhibitors in Cancer: Breakthrough and Challenges of Targeted Therapy. Cancers. doi:10.3390/cancers12030731 Peer Reviewed verified by ORBi* These authors have contributed equally to this work. |
 | GENNIGENS, C., DE CUYPERE, M., HERMESSE, J., Barbeaux, A., Forget, F., KRIDELKA, F., & JERUSALEM, G. (February 2020). Impact of hemoglobin level and red blood cell transfusions in patients with locally advanced cervical cancer treated by chemoradiotherapy [Poster presentation]. 22nd Annual BSMO meeting, Gent, Belgium. |
 | Ribi, K., Luo, W., Colleoni, M., Karlsson, P., Chirgwin, J., Aebi, S., Jerusalem, G., Neven, P., Di Lauro, V., Gomez, H. L., Ruhstaller, T., Abdi, E., Biganzoli, L., Müller, B., Barbeaux, A., Graas, M.-P., Rabaglio, M., Francis, P. A., Foukakis, T., ... Bernhard, J. (2020). Correction: Quality of life under extended continuous versus intermittent adjuvant letrozole in lymph node-positive, early breast cancer patients: the SOLE randomised phase 3 trial. British Journal of Cancer, 122 (7), 1119. doi:10.1038/s41416-019-0709-x Peer Reviewed verified by ORBi |
 | Slamon, D. J., & Jerusalem, G. (2020). Ribociclib plus Fulvestrant in Advanced Breast Cancer. Reply. The New England journal of medicine, 382 (23), 85. doi:10.1056/NEJMc2004229 Peer reviewed |
 | Hamilton, E., Cortes, J., Ozyilkan, O., Chen, S.-C., Petrakova, K., Manikhas, A., Jerusalem, G., Hegg, R., Huober, J., Chapman, S. C., Lu, Y., Hardebeck, M. C., Bear, M. M., Johnston, E. L., & Martin, M. (2020). nextMONARCH: Abemaciclib Monotherapy or Combined With Tamoxifen for Metastatic Breast Cancer. Clinical Breast Cancer. doi:10.1016/j.clbc.2020.09.011 Peer Reviewed verified by ORBi |
 | Gennigens, C., DE CUYPERE, M., SEIDEL, L., HERMESSE, J., Barbeaux, A., Forget, F., Albert, A., Jerusalem, G., & Kridelka, F. (2020). Correlation between hematological parameters and outcome in patients with locally advanced cervical cancer treated by concomitant chemoradiotherapy. Cancer Medicine, 1-12. doi:10.1002/cam4.3465 Peer Reviewed verified by ORBi |
 | Verschraegen, C. F., Jerusalem, G., McClay, E. F., Iannotti, N., Redfern, C. H., Bennouna, J., Chen, F. L., Kelly, K., Mehnert, J., Morris, J. C., Taylor, M., Spigel, D., Wang, D., Grote, H. J., Zhou, D., Munshi, N., Bajars, M., & Gulley, J. L. (2020). Efficacy and safety of first-line avelumab in patients with advanced non-small cell lung cancer: results from a phase Ib cohort of the JAVELIN Solid Tumor study. Journal for ImmunoTherapy of Cancer, 8 (2). doi:10.1136/jitc-2020-001064 Peer Reviewed verified by ORBi |
 | ONESTI, C. E., SCHROEDER, H., RORIVE, A., SAUTOIS, B., LECOCQ, M., Goffin, M., GONNE, E., COLLINGE, A., NICOLAERS, L., WERA, O., Catot, A., LOLY, C., PAULUS, A., SIBILLE, A., LOUSBERG, L., Troisfontaine, F., COLLIGNON, J., GENNIGENS, C., FRERES, P., & JERUSALEM, G. (2020). How do oncological patients perceive the Covid-19 (SARS-CoV-2) pandemic ? Experience from CHU Liege in Belgium [Poster presentation]. ESMO Virtual Congress 2020, Madrid, Spain. |
 | LECOCQ, M., ONESTI, C. E., SCHROEDER, H., RORIVE, A., Goffin, M., GONNE, E., SAUTOIS, B., Catot, A., WERA, O., NICOLAERS, L., COLLINGE, A., Collignon, J., FRERES, P., POLUS, M., DUYSINX, B., VAILLANT, F., GENNIGENS, C., MARCHAL, N., PONCIN, A., & JERUSALEM, G. (2020). Risk of SARS-CoV-2 infection and outcome after infection : Experience from the day-care unit at CHU Liege in Belgium [Poster presentation]. ESMO Virtual Congress 2020, Madrid, Spain. |
 | Schroyen, S., Letenneur, L., Missotten, P., Jerusalem, G., & Adam, S. (2020). Impact of self-perception of aging on mortality of older patients in oncology. Cancer Medicine, 9, 2283-2289. doi:10.1002/cam4.2819 Peer Reviewed verified by ORBi |
 | Corona, S. P., Giudici, F., JERUSALEM, G., Ciruelos, E., Strina, C., Sirico, M., Bernocchi, O., Milani, M., Dester, M., Ziglioli, N., Barbieri, G., Cervoni, V., Montemurro, F., & Generali, D. (2020). Impact of BMI on the outcome of metastatic breast cancer patients treated with everolimus : a retrospective exploratory analysis of the BALLET study. Oncotarget, 11 (23), 2172-2181. doi:10.18632/oncotarget.27612 Peer Reviewed verified by ORBi |
 | Schettini, F., Sobhani, N., Ianza, A., Triulzi, T., Molteni, A., Lazzari, M. C., Strina, C., Milani, M., Corona, S. P., Sirico, M., Bernocchi, O., Giudici, F., Cappelletti, M. R., Ciruelos, E., Jerusalem, G., Loi, S., Fox, S. B., & Generali, D. (2020). Immune system and angiogenesis-related potential surrogate biomarkers of response to everolimus-based treatment in hormone receptor-positive breast cancer: an exploratory study. Breast Cancer Research and Treatment, 184 (2), 421-431. doi:10.1007/s10549-020-05856-3 Peer Reviewed verified by ORBi |
 | Fasching, P. A., Beck, J. T., Chan, A., De Laurentiis, M., Esteva, F. J., Jerusalem, G., Neven, P., Pivot, X., Bianchi, G. V., Martin, M., Chandiwana, D., Lanoue, B., Ridolfi, A., Wang, Y., Rodriguez Lorenc, K., & Nusch, A. (2020). Ribociclib plus fulvestrant for advanced breast cancer: Health-related quality-of-life analyses from the MONALEESA-3 study. Breast (Edinburgh, Scotland), 54, 148-154. doi:10.1016/j.breast.2020.09.008 Peer reviewed |
 | ONESTI, C. E., JOSSE, C., Boulet, D., Thiry, J., Beaumecker, B., BOURS, V., & JERUSALEM, G. (2020). Blood eosinophilic relative count is prognostic for breast cancer and associated with the presence of tumor at diagnosis and at time of relapse. Oncoimmunology. doi:10.1080/2162402X.2020.1761176 Peer Reviewed verified by ORBi |
 | JERUSALEM, G. (2020). Organisation des soins en cancérologie dans le contexte de la COVID-19 : expérience au CHU de Liège. Revue Médicale de Liège. Supplément, 75, 38-S40. Peer reviewed |
 | Slamon, D. J., Neven, P., Chia, S., Fasching, P. A., De Laurentiis, M., Im, S.-A., Petrakova, K., Bianchi, G. V., Esteva, F. J., Martin, M., Nusch, A., Sonke, G. S., De la Cruz-Merino, L., Beck, J. T., Pivot, X., Sondhi, M., Wang, Y., Chakravartty, A., Rodriguez-Lorenc, K., ... Jerusalem, G. (2020). Overall Survival with Ribociclib plus Fulvestrant in Advanced Breast Cancer. The New England journal of medicine, 382 (6), 514-524. doi:10.1056/NEJMoa1911149 Peer reviewed |
 | PONCIN, A., & Jerusalem, G. (2020). Evolution des thérapies anti-cancéreuses systémiques. Revue Médicale de Liège, 75 (5-6), 466-472. Peer reviewed |
 | Ciruelos, E., Jerusalem, G., Martin, M., Tjan-Heijnen, V. C. G., Neven, P., Gavila, J., Montemurro, F., Generali, D., Lang, I., Martínez-Serrano, M. J., Perelló, M. F., & Conte, P. (2020). Everolimus plus exemestane in hormone-receptor-positive, HER2-negative locally advanced or metastatic breast cancer: incidence and time course of adverse events in the phase IIIb BALLET population. Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 22 (10), 1857-1866. doi:10.1007/s12094-020-02327-5 Peer reviewed |
 | Grégoire, C., Faymonville, M.-E., VANHAUDENHUYSE, A., CHARLAND-VERVILLE, V., Jerusalem, G., Dardenne, N., & Bragard, I. (26 September 2019). Effects of a hypnosis-based intervention on fatigue and sleep difficulties in post-treatment cancer patients [Poster presentation]. 21st World Congress of Psycho-Oncology, Banff, Canada. Peer reviewed |
| Grégoire, C., FAYMONVILLE, M.-E., VANHAUDENHUYSE, A., Charland-Verville, V., JERUSALEM, G., Dardenne, N., & Bragard, I. (September 2019). Effects of a hypnosis-based intervention on fatigue and sleep difficulties in post-treatment cancer patients. Journal of Psychosocial Oncology Research and Practice, 1 (1S). Peer reviewed |
Goosse, M., Ortiz Halabi, I., BARTHELEMY, N., Guillaume, M., GHUYSEN, A., JERUSALEM, G., & Bragard, I. (10 July 2019). A virtual patient to enhance physicians training in breaking bad news in oncology [Paper presentation]. Simulation Congress 2019, Liege, Belgium. |
 | Bicego, A. Y., GREGOIRE, C., Cassol, H., FAYMONVILLE, M.-E., Nyssen, A.-S., Rousseaux, F., JERUSALEM, G., LAUREYS, S., Bragard, I., & VANHAUDENHUYSE, A. (08 July 2019). Study of the impact of non-pharmacological techniques (self-hypnosis/self-care) on cognitive complaints in cancer patients [Paper presentation]. 15th European Conference on Psychological Assessment. Peer reviewed |
Goosse, M., Ortiz Halabi, I., BARTHELEMY, N., Guillaume, M., GHUYSEN, A., JERUSALEM, G., & Bragard, I. (12 June 2019). Methodology of a virtual patient development to enhance physicians training in breaking bad news in oncology [Paper presentation]. Sesam annual meeting, Glasgow, United Kingdom. |
 | Bicego, A. Y., Grégoire, C., Cassol, H., FAYMONVILLE, M.-E., Nyssen, A.-S., Rousseaux, F., JERUSALEM, G., Laureys, S., Bragard, I., & VANHAUDENHUYSE, A. (30 May 2019). Study of the impact of non-pharmacological techniques (self-hypnosis/self-care) on cognitive complaints in cancer patients [Paper presentation]. Hypnosis New Generation, Budapest, Hungary. Peer reviewed |
 | Bicego, A. Y., Grégoire, C., Cassol, H., FAYMONVILLE, M.-E., Nyssen, A.-S., Rousseaux, F., JERUSALEM, G., LAUREYS, S., Bragard, I., & VANHAUDENHUYSE, A. (14 May 2019). Learning self-hypnosis/self-care improves cognitive complaints in cancer patients [Poster presentation]. Annual Meeting of the Belgian Association for Psychological Sciences, Liège, Belgium. Peer reviewed |
 | ONESTI, C. E., BOEMER, F., JOSSE, C., LEDUC, S., Poulet, C., BOURS, V., & JERUSALEM, G. (2019). Tryptophan catabolism differentiates breast cancer patients from healthy controls but does not predict outcome. Annals of Oncology. Peer Reviewed verified by ORBi |
 | Latge, G., Poulet, C., JOSSE, C., JERUSALEM, G., & Bours, V. (15 March 2019). Role of DNA methylation in INK4a-ARF-INK4b locus expression in breast cancer [Poster presentation]. 19th Meeting of the Belgian Society of Human Genetics, Liège, Belgium. |
 | Debit, A., Poulet, C., JOSSE, C., Azencott, C.-A., Jerusalem, G., Van Steen, K., & BOURS, V. (15 March 2019). TOWARDS AN ACCURATE CANCER DIAGNOSIS MODELIZATION:COMPARISON OF RANDOM FOREST STRATEGIES [Poster presentation]. 19th BeSHG meeting 15th March 2019 Liege, Belgium, Liege, Belgium. |
 | Van Ryckeghem, F., Haverbeke, C., Wynendaele, W., JERUSALEM, G., Somers, L., Van den broeck, A., Vingerhoedt, S., & Van Belle, S. (2019). Real-world use of granulocyte colony-stimulating factor in ambulatory breast cancer patients: a cross-sectional study. Supportive Care in Cancer, 27, 1099-1108. doi:10.1007/s00520-018-4399-3 Peer Reviewed verified by ORBi |
 | GENNIGENS, C., KRIDELKA, F., JERUSALEM, G., SEIDEL, L., GOFFIN, F., Barbeaux, A., Forget, F., KAKKOS, A., HERMESSE, J., GONNE, E., & DE CUYPERE, M. (2019). Lymphocytes count at diagnosis is a potential survival predictor in patients treated by chemoradiation in locally advanced cervical cancer [Poster presentation]. ESGO 2019 Athens: 21st European Gynaecological Oncology Congress 2019, Athens, Greece. |
 | Awada, A., Gligorov, J., Jerusalem, G., Preusser, M., Singer, C., & Zielinski, C. (2019). CDK4/6 inhibition in low burden and extensive metastatic breast cancer: summary of an ESMO Open-Cancer Horizons pro and con discussion. ESMO Open, 4 (6), 000565. doi:10.1136/esmoopen-2019-000565 Peer Reviewed verified by ORBi |
 | ONESTI, C. E., FRERES, P., & JERUSALEM, G. (2019). Atypical patterns of response to immune checkpoint inhibitors: interpreting pseudoprogression and hyperprogression in decision making for patients’ treatment. Journal of Thoracic Disease. doi:10.21037/jtd.2018.12.47 Peer Reviewed verified by ORBi |
 | Kaufman, P. A., Wildiers, H., Freyer, G., Kemeny, M., Goncalves, A., JERUSALEM, G., Stopeck, A., Vrindavanam, N., Dalenc, F., Nanayakkara, N., Wu, B., & Pickett, C. A. (2019). Phase 1b Study of Trebananib Plus Paclitaxel and Trastuzumab in Patients With HER2-Positive Locally Recurrent or Metastatic Breast Cancer. Clinical Breast Cancer, 19 (1), 47-57. doi:10.1016/j.clbc.2018.09.012 Peer Reviewed verified by ORBi |
 | Jerusalem, G., Lancellotti, P., & Kim, S.-B. (2019). HER2+ breast cancer treatment and cardiotoxicity: monitoring and management. Breast Cancer Research and Treatment. doi:10.1007/s10549-019-05303-y Peer Reviewed verified by ORBi |
 | Ribi, K., Luo, W., Colleoni, M., Karlsson, P., Chirgwin, J. H., Aebi, S., JERUSALEM, G., Neven, P., Di Lauro, V., Gomez, H. L., Ruhstaller, T., Abdi, E., Biganzoli, L., Müller, B., Barbeaux, A., Graas, M.-P., Rabaglio, M., Francis, P. A., Foukakis, T., ... on behalf of the SOLE Investigators. (2019). Quality of life under extended continuous versus intermittent adjuvant letrozole in lymph node-positive, early breast cancer patients: the SOLE randomised phase 3 trial. British Journal of Cancer, 120, 959-967. doi:10.1038/s41416-019-0435-4 Peer Reviewed verified by ORBi |
 | Loi, S., Giobbie-Hurder, A., Gombos, A., Bachelot, T., Hui, R., Curigliano, G., Campone, M., Biganzoli, L., Bonnefoi, H., JERUSALEM, G., Bartsch, R., Rabaglio-Poretti, M., Kammler, R., Maibach, R., Smyth, M. J., Di Leo, A., Colleoni, M., Viale, G., Regan, M. M., ... International Breast Cancer Study Group and the Breast International Group. (2019). Pembrolizumab plus trastuzumab in trastuzumab-resistant, advanced, HER2-positive breast cancer (PANACEA): a single-arm, multicentre, phase 1b–2 trial. The Lancet Oncology, 20 (3), 371-382. doi:10.1016/S1470-2045(18)30812-X Peer Reviewed verified by ORBi |
 | GENNIGENS, C., & JERUSALEM, G. (2019). State of the art in the treatment of soft tissue sarcomas. Belgian Journal of Medical Oncology, 13 (6), 227-233. Peer Reviewed verified by ORBi |
 | Quinten, C., Kenis, C., Decoster, L., Debruyne, P. R., De Groof, I., Focan, C., Cornelis, F., Verschaeve, V., Bachmann, C., Bron, D., Luce, S., Debugne, G., Van den Bulck, H., Goeminne, J. C., Baitar, A., Geboers, K., Petit, B., Langenaeken, C., Van Rijswijk, R., ... Wildiers, H. (2019). Determining clinically important differences in health-related quality of life in older patients with cancer undergoing chemotherapy or surgery. Quality of Life Research, 28 (3), 663-676. doi:10.1007/s11136-018-2062-6 Peer Reviewed verified by ORBi |
 | FOIDART, P., Yip, C., Radermacher, J., Blacher, S., Lienard, M., MONTERORUIZ, L., Maquoi, E., Montaudon, E., Chateau-Joubert, S., COLLIGNON, J., Coibion, M., Jossa, V., Marangoni, E., Noël, A., Sounni, N. E.* , & JERUSALEM, G.*. (2019). Expression of MT4-MMP, EGFR, and RB in Triple-Negative Breast Cancer Strongly Sensitizes Tumors to Erlotinib and Palbociclib Combination Therapy. Clinical Cancer Research. doi:10.1158/1078-0432.CCR-18-1880 Peer Reviewed verified by ORBi* These authors have contributed equally to this work. |
 | Lancellotti, P., Suter, T. M., Lopez-Fernandez, T., Galderisi, M., Lyon, A. R., Van der Meer, P., Cohen Solal, A., Zamorano, J.-L., Jerusalem, G., Moonen, M., Aboyans, V., Bax, J. J., & Asteggiano, R. (2019). Cardio-Oncology Services: rationale, organization, and implementation: A report from the ESC Cardio-Oncology council. European Heart Journal. doi:10.1093/eurheartj/ehy453 Peer Reviewed verified by ORBi |
 | Kirschbrown, W. P., Kågedal, M., Wang, B., Lindbom, L., Knott, A., Mack, R., Monemi, S., Nijem, I., Girish, S., Freeman, C., Fumagalli, D., McConnell, R., JERUSALEM, G., Twelves, C., Baselga, J., von Minckwitz, G., Bines, J., & Garg, A. (2019). Pharmacokinetic and exploratory exposure–response analysis of pertuzumab in patients with operable HER2-positive early breast cancer in the APHINITY study. Cancer Chemotherapy and Pharmacology, 83 (6), 1147-1158. doi:10.1007/s00280-019-03826-1 Peer Reviewed verified by ORBi |
 | Decoster, L., Quinten, C., Kenis, C., Flamaing, J., Debruyne, P. R., De Groof, I., Focan, C., Cornelis, F., Verschaeve, V., Bachmann, C., Bron, D., Luce, S., Debugne, G., Van den Bulck, H., Goeminne, J.-C., Baitar, A., Geboers, K., Petit, B., Langenaeken, C., ... Wildiers, H. (2019). Health related quality of life in older patients with solid tumors and prognostic factors for decline. Journal of Geriatric Oncology. doi:10.1016/j.jgo.2019.03.018 Peer Reviewed verified by ORBi |
 | ONESTI, C. E., BOEMER, F., JOSSE, C., LEDUC, S., BOURS, V., & JERUSALEM, G. (2019). Tryptophan catabolism increases in breast cancer patients compared to healthy controls without affecting the cancer outcome or response to chemotherapy. Journal of Translational Medicine, 17, 239. doi:10.1186/s12967-019-1984-2 Peer Reviewed verified by ORBi |
 | Giuliano, M., Schettini, F., Rognoni, C., Milani, M., Jerusalem, G., Bachelot, T., De Laurentiis, M., Thomas, G., De Placido, P., Arpino, G., De Placido, S., Cristofanilli, M., Giordano, A., Puglisi, F., Pistilli, B., Prat, A., Del Mastro, L., Venturini, S., & Generali, D. (2019). Endocrine treatment versus chemotherapy in postmenopausal women with hormone receptor-positive, HER2-negative, metastatic breast cancer: a systematic review and network meta-analysis. The Lancet Oncology, 20, 1360-1369. doi:10.1016/S1470-2045(19)30420-6 Peer Reviewed verified by ORBi |
 | Antonia, S. J., Balmanoukian, A., Brahmer, J., Ou, S.-H. I., Hellmann, M. D., Kim, S.-W., Ahn, M.-J., Kim, D.-W., Gutierrez, M., Liu, S. V., Schoffski, P., Jager, D., Jamal, R., Jerusalem, G., Lutzky, J., Nemunaitis, J., Calabro, L., Weiss, J., Gadgeel, S., ... Segal, N. H. (2019). Clinical Activity, Tolerability, and Long-term Follow-up of Durvalumab in Patients With Advanced NSCLC. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 14 (10), 1794-1806. doi:10.1016/j.jtho.2019.06.010 Peer reviewed |
 | Rolfo, C., de Vos-Geelen, J., Isambert, N., Molife, L. R., Schellens, J. H. M., De Grève, J., Dirix, L., Grundtvig-Sørensen, P., JERUSALEM, G., Leunen, K., Mau-Sørensen, M., Plummer, R., Learoyd, M., Bannister, W., Fielding, A., & Ravaud, A. (2019). Pharmacokinetics and Safety of Olaparib in Patients with Advanced Solid Tumours and Renal Impairment. Clinical Pharmacokinetics. doi:10.1007/s40262-019-00754-4 Peer Reviewed verified by ORBi |
 | Grégoire, C., Faymonville, M.-E., VANHAUDENHUYSE, A., Charland-Verville, V., Jerusalem, G., & Bragard, I. (15 November 2018). Randomized controlled trial of an 8-week intervention combining self-care and hypnosis for post-treatment cancer patients: study protocol. BMC Cancer, 18 (1113). doi:10.1186/s12885-018-5046-6 Peer Reviewed verified by ORBi |
Debit, A., Poulet, C., JOSSE, C., Van Steen, K., JERUSALEM, G., Bours, V., & Azencott, C.-A. (05 October 2018). Towards an accurate cancer diagnosis modelization: Comparison of Random Forest strategies [Poster presentation]. 5th conference Bioinformatics for young international researchers expo byteMAL 2018, Liege, Belgium. |
 | LECLERC, A.-F., Slomian, J., JERUSALEM, G., COUCKE, P., BURY, T., Deflandre, D., DEVOS, M., Bruyère, O., Foidart-Dessalle, M., KAUX, J.-F., Crielaard, J.-M., & Maquet, D. (October 2018). Exercise and Education Program After Breast Cancer: Benefits on Quality of Life and Symptoms at 3, 6, 12, and 24 Months' Follow-up. Clinical Breast Cancer, 18 (5), 1189-e1204. doi:10.1016/j.clbc.2018.05.004 Peer Reviewed verified by ORBi |
 | Neven, P., Petrakova, K., Bianchi, G. V., De La Cruz Merino, L., JERUSALEM, G., Beck, J. T., Sonke, G. S., Chia, S., Brucker, S., Wang, Y., He, W., Rodriguez Lorenc, K., Su, F., & Im, S.-A. (October 2018). Ribociclib + Fulvestrant in hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer : MONALEESA-3 biomarker analyses. Annals of Oncology, 29 (supplement 8), 113 - viii 114. Peer Reviewed verified by ORBi |
 | ONESTI, C. E., JOSSE, C., Poncin, A., FRERES, P., Poulet, C., BOURS, V., & JERUSALEM, G. (2018). Predictive and prognostic role of peripheral blood eosinophil count in triple-negative and hormone receptor-negative/HER2-positive breast cancer patients undergoing neoadjuvant treatment. Oncotarget. doi:10.18632/oncotarget.26120 Peer Reviewed verified by ORBi |
 | Latgé, G., JOSSE, C., Poulet, C., Bours, V., & Jerusalem, G. (13 September 2018). Role of DNA methylation in INK4a-ARF-INK4b locus expression in breast cancer [Poster presentation]. GIGA-Cancer DAY, Liege, Belgium. |
 | Debit, A., JOSSE, C., JERUSALEM, G., BOURS, V., & Poulet, C. (13 September 2018). Towards an accurate cancer diagnosis modelization:Comparison of Random Forest strategies [Poster presentation]. JOINT MEETING GIGA-CANCER DAY 2018 / EDT-CANCEROLOGY, Liege, Belgium. |
 | ONESTI, C. E., JOSSE, C., PONCIN, A., FRERES, P., Poulet, C., BOURS, V., & JERUSALEM, G. (13 September 2018). Predictive and prognostic role of peripheral blood eosinophil count in triple negative and hormone receptor negative/HER2 positive breast cancers patients undergoing neoadjuvant treatment [Paper presentation]. GIGA-Cancer Day 2018 / EDT-Cancerology Vascular landscape and (pre)metastatic niche in cancer biology. |
 | Rapino, F., Delaunay, S., Rambow, F., Zhou, Z., Tharun, L., De Tullio, P., Sin, O., Shostak, K., Schmitz, S., Piepers, J., Guesquière, B., Karim, L., Charloteaux, B., Jamart, D., Florin, A., Lambert, C., RORIVE, A., JERUSALEM, G., Leucci, E., ... Close, P. (28 June 2018). Codon-specific translation reprogramming promotes resistance to targeted therapy. Nature, 558, 605-609. doi:10.1038/s41586-018-0243-7 Peer Reviewed verified by ORBi |
 | Kenis, C., Decoster, L., Flamaing, J., Debruyne, P. R., De Groof, I., Focan, C., Cornelis, F., Verschaeve, V., Bachmann, C., Bron, D., Luce, S., Debugne, G., Van den Bulck, H., Goeminne, J.-C., Schrijvers, D., Geboers, K., Petit, B., Langenaeken, C., Van Rijswijk, R., ... Wildiers, H. (2018). Adherence to geriatric assessment-based recommendations in older patients with cancer: a multicenter prospective cohort study in Belgium. Annals of Oncology. doi:10.1093/annonc/mdy210 Peer Reviewed verified by ORBi |
| FOIDART, P., Yip, C., Radermacher, J., MONTERORUIZ, L., Coibion, M., Jossa, V., Marangoni, E., Noël, A., Sounni, N. E., & JERUSALEM, G. (24 February 2018). MT4-MMP, EGFR and RB expressions are predictive biomarkers of response to Erlotinib-Palbociclib combination in TNBC [Paper presentation]. Belgian Society of Medical Oncology: annual meeting, Ostende, Belgium. |
 | FOIDART, P., Yip, C., Radermacher, J., MONTERORUIZ, L., Marangoni, E., Noël, A., Sounni, N. E., JERUSALEM, G., Coibion, M., Jossa, V., & BLACHER, S. (27 January 2018). Expression of MT4-MMP, EGFR and Rb in triple negative breast cancers strongly sensitizes tumors to Erlotinib and Palbociclib combination therapy [Paper presentation]. Belgian Association for Cancer Research : Annual Meeting, Liège, Belgium. |
 | Plummer, R., Verheul, H. M., De Vos, F. Y. F. L., Leunen, K., Molife, L. R., Rolfo, C., Grundtvig-Sørensen, P., De Grève, J., Rottey, S., JERUSALEM, G., Italiano, A., Spicer, J., Dirix, L., Goessl, C., Birkett, J., Spencer, S., Learoyd, M., Bailey, C., & Dean, E. (2018). Pharmacokinetic Effects and Safety of Olaparib Administered with Endocrine Therapy: A Phase I Study in Patients with Advanced Solid Tumours. Advances in Therapy, 35 (11), 1945-1964. doi:10.1007/s12325-018-0804-z Peer Reviewed verified by ORBi |
 | Slamon, D. J., Neven, P., Chia, S., Fasching, P. A., De Laurentiis, M., Im, S.-A., Petrakova, K., Bianchi, G. V., Esteva, F. J., Martin, M., Nusch, A., Sonke, G. S., De la Cruz-Merino, L., Beck, J. T., Pivot, X., Vidam, G., Wang, Y., Rodriguez Lorenc, K., Miller, M., ... Jerusalem, G. (2018). Phase III Randomized Study of Ribociclib and Fulvestrant in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: MONALEESA-3. Journal of Clinical Oncology, 2018789909. doi:10.1200/JCO.2018.78.9909 Peer Reviewed verified by ORBi |
 | Catala, G., Mebis, J., JERUSALEM, G., Verhoeven, D., Awada, A., Bols, A., Somers, L., Van Den Broeck, A., Duhoux, F. P., & Machiels, J.-P. (2018). Neutropenia management in patients receiving myelosuppressive polychemotherapy for early breast cancer in Belgium: BRONS study results. Acta Clinica Belgica. doi:10.1080/17843286.2018.1563735 Peer Reviewed verified by ORBi |
 | Jerusalem, G., de Boer, R. H., Hurvitz, S., Yardley, D. A., Kovalenko, E., Ejlertsen, B., Blau, S., Ozguroglu, M., Landherr, L., Ewertz, M., Taran, T., Fan, J., Noel-Baron, F., Louveau, A.-L., & Burris, H. (2018). Everolimus Plus Exemestane vs Everolimus or Capecitabine Monotherapy for Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer: The BOLERO-6 Randomized Clinical Trial. JAMA Oncology, 182262. doi:10.1001/jamaoncol.2018.2262 Peer Reviewed verified by ORBi |
 | Gennari, A., Sun, Z., Hasler-Strub, U., Colleoni, M., Kennedy, M. J., Von Moos, R., Cortes, J., Vidal, M. J., Hennessy, B., Walshe, J., Amillano Parraga, K., Ribi, K., Bernhard, J., Morales, S. M., Pagani, O., Barbeaux, A., Borstnar, S., Rabaglio-Poretti, M., Maibach, R., ... Jerusalem, G. (2018). A randomized phase II study evaluating different maintenance schedules of nab-Paclitaxel in the first-line treatment of metastatic breast cancer: final results of the IBCSG 42-12/BIG 2-12 SNAP trial. Annals of Oncology, 29, 661-668. doi:10.1093/annonc/mdx772 Peer Reviewed verified by ORBi |
 | Di Leo, A., Jerusalem, G., Torres, R., Verhoeven, D., Pendergrass, K., Malorni, L., Lichfield, J., & Martin, M. (2018). First-line vs second-line fulvestrant for hormone receptor-positive advanced breast cancer: A post-hoc analysis of the CONFIRM study. Breast, 38, 144-149. doi:10.1016/j.breast.2017.12.016 Peer reviewed |
 | Schroyen, S.* , Adam, S.* , Marquet, M., Jerusalem, G., Thiel, S., Giraudet, A.-L., & Missotten, P. (2018). Communication of healthcare professionals: is there ageism? European Journal of Cancer Care, 27 (1), 12780. doi:10.1111/ecc.12780 Peer Reviewed verified by ORBi* These authors have contributed equally to this work. |
 | Latge, G., Poulet, C., Bours, V., JOSSE, C., & Jerusalem, G. (2018). Natural Antisense Transcripts: Molecular Mechanisms and Implications in Breast Cancers. International Journal of Molecular Sciences, 19 (1). doi:10.3390/ijms19010123 Peer Reviewed verified by ORBi |
 | Freres, P., Bouznad, N., Servais, L., JOSSE, C., Wenric, S., Poncin, A., Thiry, J., Moonen, M., Oury, C., Lancellotti, P., Bours, V., & Jerusalem, G. (2018). Variations of circulating cardiac biomarkers during and after anthracycline-containing chemotherapy in breast cancer patients. BMC Cancer, 18 (1). doi:10.1186/s12885-018-4015-4 Peer Reviewed verified by ORBi |
 | Colleoni, M., Luo, W., Karlsson, P., Chirgwin, J. H., Aebi, S., Jerusalem, G., Neven, P., Hitre, E., Graas, M.-P., Simoncini, E., Kamby, C., Thompson, A., Loibl, S., Gavila, J., Kuroi, K., Marth, C., Muller, B., O'Reilly, S., Di Lauro, V., ... Goldhirsch, A. (2018). Extended adjuvant intermittent letrozole versus continuous letrozole in postmenopausal women with breast cancer (SOLE): a multicentre, open-label, randomised, phase 3 trial. The Lancet Oncology, 19 (1), 127-138. doi:10.1016/S1470-2045(17)30715-5 Peer Reviewed verified by ORBi |
 | Loi, S., Giobbie-Hurder, A., Gombos, A., Bachelot, T., Hui, R., Curigliano, G., Campone, M., Biganzoli, L., Bonnefoi, H., JERUSALEM, G., Bartsch, R., Rabaglio-Poretti, M., Kammler, R., Maibach, R., Smyth, M., Di Leo, A., Colleoni, M., Viale, G., Regan, M., & André, F. (December 2017). Phase Ib/II study evaluating safety and efficacy of Pembrolizumab and Trastuzumab in patients with Trastuzumab-resistant HER2-positive advanced breast cancer : results from the PANACEA study (IBCSG 45-13/BIG 4-13/KEYNOTE-014) [Paper presentation]. SABCS, San Antonio, United States. |
 | Ribi, K., Luo, W., Colleoni, M., Karlsson, P., Chirgwin, J. H., Aebi, S., JERUSALEM, G., Neven, P., Di Lauro, V., Gomez, H., Ruhstaller, T., Abdi, E., Di Leo, A., Müller, B., Maibach, R., Gelber, R., Goldhirsch, A., Coates, A., Regan, M., & Bernhard, J. (December 2017). Extended continuous vs intermittent adjuvant letrozole in postmenopausal women with lymph node-positive, early breast cancer (IBCSG 37-05/BIG 1-05 SOLE) : impact on quality of life [Poster presentation]. SABCS, San Antonio, United States. |
 | Ribi, K., Sun, Z., JERUSALEM, G., Hasler, U., Colleoni, M., von Moos, R., Cortés, J., Vidal, M., Hennessey, B., Walshe, J., Amillano Parraga, K., Morales Murillo, S., Pagani, O., Barbeaux, A., Borstnar, S., Maibach, R., Regan, M., Gennari, A., & Bernhard, J. (December 2017). Nab-Paclitaxel-based therapy in the first line treatment of metastatic breast cancer (IBCSG 42-12/BIG 2-12 SNAP) : impact of different schedules on quality of life [Poster presentation]. SABCS, San Antonio, United States. |
Grégoire, C., Bragard, I., Etienne, A.-M., JERUSALEM, G., COUCKE, P., Dupuis, G., Lanctôt, D., & FAYMONVILLE, M.-E. (14 November 2017). Group interventions to reduce emotional distress and fatigue in breast cancer patients [Paper presentation]. Journée doctorale en santé publique, Bruxelles, Belgium. Peer reviewed |
 | Grégoire, C., FAYMONVILLE, M.-E., JERUSALEM, G., Bragard, I., Charland-Verville, V., & VANHAUDENHUYSE, A. (November 2017). Intérêt et utilisation de l’hypnose pour améliorer le bien-être physique et psychologique en oncologie. HEGEL: Penser par Soi-Même, 7 (4), 267-275. doi:10.4267/2042/63778 Peer Reviewed verified by ORBi |
 | Leclerc, A.-F., Foidart-Dessalle, M., Tomasella, M., Coucke, P., DEVOS, M., Bruyère, O., Bury, T., Deflandre, D., Jerusalem, G., LIFRANGE, E., KAUX, J.-F., Crielaard, J.-M., & Maquet, D. (October 2017). Multidisciplinary rehabilitation program after breast cancer: benefits on physical function, anthropometry and quality of life. European Journal of Physical and Rehabilitation Medicine, 53 (5), 633-642. doi:10.23736/S1973-9087.17.04551-8 Peer Reviewed verified by ORBi |
 | FRERES, P., GENNIGENS, C., Martin, D., & Jerusalem, G. (October 2017). Leptomeningeal carcinomatosis from solid tumours : a systematic review of the literature. Belgian Journal of Medical Oncology, 11, 259-264. Peer Reviewed verified by ORBi |
 | Grégoire, C.* , Bragard, I.* , JERUSALEM, G., Etienne, A.-M., COUCKE, P., Dupuis, G., Lanctôt, D., & FAYMONVILLE, M.-E. (19 September 2017). Group interventions to reduce emotional distress and fatigue in breast cancer patients: A nine-month follow-up pragmatic trial. British Journal of Cancer, 10 (117), 1442-1449. doi:10.1038/bjc.2017.326 Peer Reviewed verified by ORBi* These authors have contributed equally to this work. |
 | Schroyen, S.* , Missotten, P.* , Jerusalem, G., Van den Akker, M., Buntinx, F., & Adam, S. (02 September 2017). Association between self-perception of aging, view of cancer and health of older patients in oncology: A one-year longitudinal study. BMC Cancer, 17 (614). doi:10.1186/s12885-017-3607-8 Peer Reviewed verified by ORBi* These authors have contributed equally to this work. |
 | Leclerc, A.-F., KAUX, J.-F., Crielaard, J.-M., Foidart-Dessalle, M., BURY, T., Deflandre, D., COUCKE, P., LIFRANGE, E., DEVOS, M., JERUSALEM, G., & Maquet, D. (18 July 2017). Influence of a multidisciplinary post-breast cancer rehabilitation program on lifestyle and behavior faced with physical activities [Poster presentation]. 19th Euro Congress on Cancer Science and Therapy, Lisbonne, Portugal. |
 | Grégoire, C., FAYMONVILLE, M.-E., JERUSALEM, G., Etienne, A.-M., COUCKE, P., Dupuis, G., Lanctôt, D., & Bragard, I. (19 May 2017). Etude des effets à long terme de différentes interventions de groupe pour améliorer la détresse émotionnelle et la fatigue chez des patientes atteintes d’un cancer du sein [Poster presentation]. Congrès de la faculté de Psychologie, Logopédie et Sciences de l’Education de l’Université de Liège. Peer reviewed |
 | Grégoire, C., Bragard, I., VANHAUDENHUYSE, A., Charland-Verville, V., Etienne, A.-M., JERUSALEM, G., & FAYMONVILLE, M.-E. (19 May 2017). Effets d'une intervention basée sur l'hypnose sur la fatigue et la détresse de patients atteints d'un cancer : une étude contrôlée randomisée [Poster presentation]. Congrès de la faculté de Psychologie, Logopédie et Sciences de l’Education de l’Université de Liège. Peer reviewed |
 | Wenric, S., El Guendi, S., CABERG, J.-H., Bezzaou, W., Fasquelle, C., Charloteaux, B., Karim, L., Hennuy, B., FRERES, P., COLLIGNON, J., BOUKERROUCHA, M., SCHROEDER, H., Olivier, F., Jossa, V., JERUSALEM, G., JOSSE, C., & BOURS, V. (May 2017). Transcriptome wide analysis of natural antisense transcripts shows potential role in breast cancer [Poster presentation]. 50th meeting of the European Society of Human Genetics, Copenhagen, Denmark. |
 | Schroyen, S., Marquet, M., Jerusalem, G., Dardenne, B., Van den Akker, M., Buntinx, F., Adam, S.* , & Missotten, P.*. (31 January 2017). The link between self-perceptions of aging, cancer view and physical and mental health of older people with cancer: A cross-sectional study. Journal of Geriatric Oncology, 8 (1), 64-68. doi:10.1016/j.jgo.2016.09.001 Peer Reviewed verified by ORBi* These authors have contributed equally to this work. |
 | Wenric, S., ElGuendi, S., CABERG, J.-H., Bezzaou, W., Fasquelle, C., Charloteaux, B., Karim, L., Hennuy, B., FRERES, P., COLLIGNON, J., BOUKERROUCHA, M., SCHROEDER, H., OLIVIER, F., Jossa, V., Jerusalem, G., JOSSE, C., & Bours, V. (2017). Transcriptome-wide analysis of natural antisense transcripts shows their potential role in breast cancer. Scientific Reports, 7 (1), 17452. doi:10.1038/s41598-017-17811-2 Peer Reviewed verified by ORBi |
 | Dirix, L. Y., Takacs, I., Jerusalem, G., Nikolinakos, P., Arkenau, H.-T., Forero-Torres, A., Boccia, R., Lippman, M. E., Somer, R., Smakal, M., Emens, L. A., Hrinczenko, B., Edenfield, W., Gurtler, J., von Heydebreck, A., Grote, H. J., Chin, K., & Hamilton, E. P. (2017). Avelumab, an anti-PD-L1 antibody, in patients with locally advanced or metastatic breast cancer: a phase 1b JAVELIN Solid Tumor study. Breast Cancer Research and Treatment. doi:10.1007/s10549-017-4537-5 Peer Reviewed verified by ORBi |
 | Pistilli, B., Pluard, T., Urruticoechea, A., Farci, D., Kong, A., Bachelot, T., Chan, S., Han, H. S., Jerusalem, G., Urban, P., Robinson, D., Mouhaer, S. L., Tomaso, E. D., Massacesi, C., & Saura, C. (2017). Phase II study of buparlisib (BKM120) and trastuzumab in patients with HER2+ locally advanced or metastatic breast cancer resistant to trastuzumab-based therapy. Breast Cancer Research and Treatment. doi:10.1007/s10549-017-4596-7 Peer Reviewed verified by ORBi |
 | Noguchi, S., Shinohara, N., Ito, T., Ohtsu, A., Ravaux, A., JERUSALEM, G., Ohno, N., Gallo, J., Bouillaud, E., Fan, J., & Nonomura, N. (2017). Relationship between pulmonary adverse events and everolimus exposure in japanese and non-japanese patients : a meta-analysis of oncology trials. Oncology, 92 (5), 243-254. doi:10.1159/000457904 Peer Reviewed verified by ORBi |
 | BRAGARD, I., Etienne, A.-M., Faymonville, M.-E., Coucke, P., LIFRANGE, E., SCHROEDER, H., Wagener, A., Dupuis, G., & Jerusalem, G. (2017). A non-randomized comparison study of self-hypnosis, yoga and cognitive behavioral therapy to reduce emotional distress in breast cancer patients. International Journal of Clinical and Experimental Hypnosis, 65 (2), 189-209. doi:10.1080/00207144.2017.1276363 Peer Reviewed verified by ORBi |
 | Lancellotti, P., Galderisi, M., Donal, E., Edvardsen, T., Popescu, B. A., Farmakis, D., Filippatos, G., Habib, G., Lestuzzi, C., Santoro, C., MOONEN, M., Jerusalem, G., Andarala, M., & Anker, S. D. (2017). Protocol update and preliminary results of EACVI/HFA Cardiac Oncology Toxicity (COT) Registry of the European Society of Cardiology. ESC Heart Failure, 4 (3), 312-318. doi:10.1002/ehf2.12162 Peer Reviewed verified by ORBi |
 | Yip, C., Foidart, P., Somja, J., Truong, A., Lienard, M., Feyereisen, E., SCHROEDER, H., GOFFLOT, S., Donneau, A.-F., COLLIGNON, J., Delvenne, P., Sounni, N. E., Jerusalem, G., & Noël, A. (2017). MT4-MMP and EGFR expression levels are key biomarkers for breast cancer patient response to chemotherapy and erlotinib. British Journal of Cancer. doi:10.1038/bjc.2017.23 Peer Reviewed verified by ORBi |
 | Leclerc, A.-F., JERUSALEM, G., DEVOS, M., CRIELAARD, J.-M., & Maquet, D. (December 2016). Multidisciplinary management of breast cancer. Archives of Public Health, 74, 50. doi:10.1186/s13690-016-0163-7 Peer Reviewed verified by ORBi |
 | Leclerc, A.-F., Foidart-Dessalle, M., BURY, T., Deflandre, D., COUCKE, P., JERUSALEM, G., LIFRANGE, E., DEVOS, M., CRIELAARD, J.-M., & Maquet, D. (2016). Influence d'un programme de revalidation multidisciplinaire post-cancer du sein sur la fonction physique. In 9ème Congrès commun SFMES - SFTS : Abstract book (pp. 43). |
 | FRERES, P., LOUSBERG, L., & JERUSALEM, G. (July 2016). Cyclin-dependent protein kinase inhibitors in breast cancer treatment. Belgian Journal of Medical Oncology, 10 (4), 132-138. Peer Reviewed verified by ORBi |
 | Jerusalem, G., Mariani, G., Ciruelos, E. M., Martin, M., Tjan-Heijnen, V. C. G., Neven, P., Gavila, J. G., Michelotti, A., Montemurro, F., Generali, D., Simoncini, E., Lang, I., Mardiak, J., Naume, B., Camozzi, M., Lorizzo, K., Bianchetti, S., & Conte, P. (2016). Safety of Everolimus Plus Exemestane In Patients With Hormone-Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer Progressing on Prior Non-Steroidal Aromatase Inhibitors: Primary Results of a Phase 3b, Open-Label, Single-Arm, Expanded-Access Multicenter Trial (BALLET). Annals of Oncology. doi:10.1093/annonc/mdw249 Peer Reviewed verified by ORBi |
 | Andre, F., Hurvitz, S., Fasolo, A., Tseng, L.-M., Jerusalem, G., Wilks, S., O'Regan, R., Isaacs, C., Toi, M., Burris, H., He, W., Robinson, D., Riester, M., Taran, T., Chen, D., & Slamon, D. (20 June 2016). Molecular Alterations and Everolimus Efficacy in Human Epidermal Growth Factor Receptor 2-Overexpressing Metastatic Breast Cancers: Combined Exploratory Biomarker Analysis From BOLERO-1 and BOLERO-3. Journal of Clinical Oncology, 34 (18), 2115-24. doi:10.1200/JCO.2015.63.9161 Peer Reviewed verified by ORBi |
 | Kelly, K., Patel, M., Infante, J. R., Iannotti, N., Nikolinakos, P., Leach, J., Wang, D., Chandler, J., JERUSALEM, G., Gurtler, J., Arkenau, H.-T., Bajars, M., von Heydebreck, A., Speit, I., Heery, C., & Gulley, J. L. (April 2016). Safety of avelumab (MSB0010718C), an anti-PD-L1 antibody : updated analysis from the phase Ib JAVELIN solid tumor trial [Paper presentation]. American Association for Cancer Research Annual Meeting, New Orleans, United States. |
 | Schroyen, S., Adam, S., Marquet, M., Jerusalem, G., Thiel, S., Giraudet, A.-L., & Missotten, P. (11 March 2016). Ageism and communication in oncology [Poster presentation]. Official 10th European Breast Cancer Conference (EBCC-10). |
 | Neven, P., Generali, D., Ciruelos, E. M., Lang, I., Gavila, J., Bighin, C., Borms, M., Conte, P., Montemurro, F., Sartori, D., Marini, L., Camozzi, M., Lorizzo, K., Ocak, O., & JERUSALEM, G. (2016). Everolimus (EVE) plus exemestane (EXE) in elderly patients (pts) with hormone receptor-positive (HR+), human epidermal growth receptor-2 negative (HER2-) advanced breast cancer (ABC) progressing on prior nonsteroidal aromatase inhibitors (NSAIs) : Insights on safety from BALLET (CRAD001YIC04) [Paper presentation]. Miami Breast Cancer Conference, Miami, United States. |
 | Dirix, L., Swaisland, H., Verheul, H. M. W., Rottey, S., Leunen, K., Jerusalem, G., Rolfo, C., Nielsen, D., Molife, L. R., Kristeleit, R., de Vos-Geelen, Mau-Sorensen, M., Soetekouw, P., van Herpen, C., Fielding, A., So, K., Bannister, W., & Plummer, R. (2016). Effect of Itraconazole and Rifampin on the Pharmacokinetics of Olaparib in Patients With Advanced Solid Tumors: Results of Two Phase I Open-Label Studies. Clinical Therapeutics, 38 (10), 2286-2299. doi:10.1016/j.clinthera.2016.08.010 Peer Reviewed verified by ORBi |
 | COLLIGNON, J., LOUSBERG, L., SCHROEDER, H., & JERUSALEM, G. (2016). Triple-negative breast cancer : treatment challenges and solutions. Breast Cancer, 8, 93-107. doi:10.2147/BCTT.S69488 Peer Reviewed verified by ORBi |
 | GONNE, E., COLLIGNON, J., JERUSALEM, G., & GENNIGENS, C. (2016). Le carcinome de site primitif inconnu, une entité pas si rare. Revue Médicale de Liège, 71 (10), 449-454. Peer reviewed |
 | Baitar, A., Kenis, C., Moor, R., Decoster, L., Luce, S., Bron, D., Van Rijswijk, R., Rasschaert, M., Langenaeken, C., Jerusalem, G., Lobelle, J.-P., Flamaing, J., Milisen, K., & Wildiers, H. (2016). Corrigendum to "Implementation of geriatric assessment-based recommendations in older patients with cancer: A multicenter prospective study" [J. Geriatr. Oncol. 6 (2015) 401-410]. Journal of Geriatric Oncology, 7 (2), 142-3. doi:10.1016/j.jgo.2016.01.005 Peer Reviewed verified by ORBi |
 | Lousberg, L., & Jerusalem, G. (2016). Safety, Efficacy, and Patient Acceptability of Everolimus in the Treatment of Breast Cancer. Breast Cancer: Basic and Clinical Research, 10, 239-252. doi:10.4137/BCBCR.S12443 Peer Reviewed verified by ORBi |
 | Fasching, P. A., JERUSALEM, G., Pivot, X., Martin, M., De Laurentiis, M., Blackwell, K., Esteva, F. J., Paquet-Luzy, T., Tang, Z., Lorenc, K. R., & Slamon, D. J. (2016). Phase III study of Ribociclib (LEE011) in combination with Fulvestrant for the treatment of postmenopausal patients (pts) with hormone receptor-positive (HR+), HER2-negative (HER2-) advanced breast cancer (ABC) who have received no or only one line of prior endocrine treatment : MONALEESA-3. Clinical Cancer Research, 2-01-02. Peer Reviewed verified by ORBi |
 | Neven, P., Generali, D., Ciruelos, E. M., Lang, I., Gavila, J., Bighin, C., Borms, M., Conte, P., Montemurro, F., Sartori, D., Marini, L., Camozzi, M., Lorizzo, K., Ocak, O., & JERUSALEM, G. (2016). Everolimus (EVE) plus exemestane (EXE) in elderly patients (pts) with hormone receptor-positive (HR+), human epidermal growth receptor-2 negative (HER2-) advanced breast cancer (ABC) progressing on prior nonsteroidal aromatase inhibitors (NSAIs) : Insights on safety form BALLET (CRAD001YIC04) [Paper presentation]. Miami Breast Cancer Conference, Miami, United States. |
 | Verschraegen, C., Chen, F. L., Spigel, D. R., Iannotti, N., McClay, E., Redfern, C. H., Bennouna, J., Taylor, M., Kaufman, H., Kelly, K., Bajars, M., von Heydebreck, A., Cuillerot, J.-M., & JERUSALEM, G. (2016). Avelumab (MSB0010718C ; anti-PD-L1) as a first-line treatment for patients with advanced NSCLC from the JAVELIN Solid Tumor phase 1b trial : safety, clinical activity, and PD-L1 expression. Journal of Clinical Oncology, 34, 9036. Peer Reviewed verified by ORBi |
 | FRERES, P., PONCIN, A., MOONEN, M., Josse, C., Oury, C., BOURS, V., LANCELLOTTI, P., & JERUSALEM, G. (2016). La cardiotoxicité des traitements anti-cancéreux. Revue Médicale de Liège, 71 (9), 382-387. Peer reviewed |
 | Bourcy, M., Suarez-Carmona, M., Lambert, J., Francart, M.-E., SCHROEDER, H., Delierneux, C., Skrypek, N., Thompson, E. W., JERUSALEM, G., Berx, G., Thiry, M., Blacher, S., Hollier, B. G., Noël, A., Oury, C., Polette, M., & Gilles, C. (2016). Tissue factor induced by epithelial-mesenchymal transition triggers a pro-coagulant state that drives metastasis of circulating tumor cells. Cancer Research, 76 (14), 4270-4282. Peer Reviewed verified by ORBi |
MOONEN, M., Frere, P., Lancellotti, P., & Jerusalem, G. (2016). Cardiac Monitoring During Clinical Trials. In Anticancer Treatments and Cardiotoxicity 1st Edition Mechanisms, Diagnostic and Therapeutic Interventions (pp. 387-399). Elsevier Inc. doi:10.1016/B978-0-12-802509-3.00039-X Peer reviewed |
 | Lancellotti, P., Moonen, M., & Jerusalem, G. (2016). Predicting Reversibility of Anticancer Drugs-Related Cardiac Dysfunction: A New Piece to the Routine Use of Deformation Imaging. Echocardiography, 33 (4), 504-9. doi:10.1111/echo.13187 Peer Reviewed verified by ORBi |
 | Plummer, R., Verheul, H. M., Langenberg, M., Leunen, K., Molife, L. R., Rolfo, C., Grundtvig-Soerensen, P., De Greve, J., Rottey, S., JERUSALEM, G., Itiliano, A., Spicer, J., Dirix, L., Goessl, C., Birkett, J., Spencer, S., Learoyd, M., & Dean, E. (2016). Pharmacokinetic (PK) effects and safety of olaparib in combination with tamoxifen, anastrozole or letrozole : Phase I study. Journal of Clinical Oncology, 34, 2562. Peer Reviewed verified by ORBi |
 | Fasching, P. A., JERUSALEM, G., Pivot, X., Martin, M., De Laurentiis, M., Blackwell, K. L., Esteva, F. J., Chia, S. K. L., Germa, C., Tang, Z., Dhuria, S. V., & Slamon, D. J. (2016). Phase III study of Ribociclib (LEE011) plus Fulvestrant for the treatment of postmenopausal patients with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer who have received no or only one line of prior endocrine treatment : MONALEESA-3. Journal of Clinical Oncology, 34, 624. Peer Reviewed verified by ORBi |
 | Earley, A., Caceres, V., Burnett, H., Higuchi, K., Wang, J., & JERUSALEM, G. (2016). Impact of chemotherapy (CT) on symptoms and health-related quality of life (HRQOL) in patients (pts) with advanced breast cancer (ABC) : A systematic review [Paper presentation]. Miami Breast Cancer Conference, Miami, United States. |
 | Bragard, I., Etienne, A.-M., Faymonville, M.-E., Coucke, P., DEVOS, M., LIFRANGE, E., SCHROEDER, H., Wagener, A., & Jerusalem, G. (2016). Etude pilote auprès de patientes atteintes d'un cancer du sein: Apport des méthodes alternatives. In A.-M. Etienne & I. Bragard, Evolutions Sociales, Innovations et Politiques: nouvelles questions et nouveaux enjeux pour la psychologie de la santé (pp. 51-54). Lyon, France: Editions des Archives Contemporaines. Peer reviewed |
 | Kenis, C., Heeren, P., Decoster, L., Van Puyvelde, K., Conings, G., Cornelis, F., Cornette, P., Moor, R., Luce, S., Libert, Y., Van Rijswijk, R., Jerusalem, G., Rasschaert, M., Langenaeken, C., Baitar, A., Specenier, P., Geboers, K., Vandenborre, K., Debruyne, P. R., ... Wildiers, H. (2016). A Belgian Survey on Geriatric Assessment in Oncology Focusing on Large-Scale Implementation and Related Barriers and Facilitators. Journal of Nutrition, Health and Aging, 20 (1), 60-70. doi:10.1007/s12603-016-0677-2 Peer Reviewed verified by ORBi |
 | Schroyen, S., Missotten, P., Jerusalem, G., GILLES, C., & Adam, S. (2016). Ageism and caring attitudes among nurses in oncology. International Psychogeriatrics, 28 (5), 749-757. doi:10.1017/S1041610215001970 Peer Reviewed verified by ORBi |
 | Schroyen, S., Missotten, P., Jerusalem, G., GILLES, C., & Adam, S. (2016). Ageism among nurses in oncology. International Psychogeriatrics. Peer Reviewed verified by ORBi |
Bourcy, M., Suarez-Carmona, M., Lambert, J., Francart, M.-E., SCHROEDER, H., Delierneux, C., Thompson, E., Jerusalem, G., Blacher, S., Noël, A., Oury, C., Polette, M., & Gilles, C. (January 2016). Epithelial-mesenchymal transition induces tissue factor and pro-coagulant properties supporting early metastasis of circulating tumor cells [Poster presentation]. GIGA-Day 2016, Belgium. |
 | Fasching, P. A., JERUSALEM, G., Pivot, X., Martin, M., De Laurentiis, M., Blackwell, K., Esteva, F. J., Germa, C., Tang, Z., Dhuria, S., & Slamon, D. J. (2016). MONALEESA-3 : A phase III study of Ribociclib (LEE011) with Fulvestrant for the treatment of hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer in postmenopausal women who have received no or only one line of prior endocrine therapy [Paper presentation]. Miami Breast Cancer Conference, Miami, United States. |
 | LOUSBERG, L., COLLIGNON, J., & Jerusalem, G. (2016). Resistance to therapy in estrogen receptor positive and human epidermal growth factor 2 positive breast cancers: progress with latest therapeutic strategies. Therapeutic Advances in Medical Oncology, 8 (6), 429-449. doi:10.1177/1758834016665077 Peer Reviewed verified by ORBi |
 | Freres, P.* , Wenric, S.* , BOUKERROUCHA, M., Fasquelle, C., Thiry, J., Bovy, N., Struman, I., Geurts, P., COLLIGNON, J., SCHROEDER, H., KRIDELKA, F., LIFRANGE, E., Jossa, V., Bours, V.* , Josse, C.* , & JERUSALEM, G.*. (2015). Circulating microRNA-based screening tool for breast cancer. Oncotarget. doi:10.18632/oncotarget.6786 Peer Reviewed verified by ORBi* These authors have contributed equally to this work. |
Francart, M.-E., Bourcy, M., Lambert, J., Suarez-Carmona, M., Jerusalem, G., Oury, C., Noël, A., & Gilles, C. (03 December 2015). Regulation of Tissue Factor by Epithelial-to-Mesenchymal Transitions: Impacts for the metastatic progression [Poster presentation]. Télévie's researchers seminar, Gembloux, Belgium. |
Yip, C., FOIDART, P., SOMJA, J., Truong, A., COLLIGNON, J., DELVENNE, P., Sounni, N. E., JERUSALEM, G., & Noël, A. (03 December 2015). MT4-MMP, a potential prognostic factor in triple negative breast cancer [Paper presentation]. Séminaire des chercheurs Télévie 2016, Gembloux, Belgium. |
 | Schroyen, S., Missotten, P., JERUSALEM, G., GILLES, C., & Adam, S. (14 October 2015). Ageism among nurses in oncology [Poster presentation]. IPA International Congress, Berlin, Germany. |
Leclerc, A.-F., FOIDART-DESSALLE, M., Bury, T., Deflandre, D., COUCKE, P., JERUSALEM, G., LIFRANGE, E., DEVOS, M., CRIELAARD, J.-M., & Maquet, D. (2015). Psychological benefits of a multidisciplinary rehabilitation program after breast cancer. In European Cancer Congress : Abstract book. |
 | Leclerc, A.-F., FOIDART-DESSALLE, M., Bury, T., Deflandre, D., COUCKE, P., JERUSALEM, G., LIFRANGE, E., DEVOS, M., CRIELAARD, J.-M., & Maquet, D. (26 September 2015). Physical benefits of a multidisciplinary rehabilitation program after breast cancer [Poster presentation]. European Cancer Congress, Vienne, Austria. |
Yip, C., PAYE, A., Truong, A., Cimino, J., COLLIGNON, J., DELVENNE, P., Jerusalem, G., Sounni, N. E., & Noël, A. (11 September 2015). Clinical significance of MT4-MMP and EGFR expression in Breast Cancer [Paper presentation]. EDT-Cancérologie Expérimentale Annual symposium « New advances in animal models in cancerology ». |
| Yip, C., FOIDART, P., SOMJA, J., Truong, A., COLLIGNON, J., DELVENNE, P., Sounni, N. E., JERUSALEM, G., & Noël, A. (September 2015). MT4-MMP, a potential therapeutic target in triple negative breast cancer [Poster presentation]. 2nd international society of cancer metabolism meeting - METABOLISM and MICROENVIRONMENT in CANCER PLASTICITY, Venise, Italy. |
Yip, C., PAYE, A., Truong, A., Cimino, J., COLLIGNON, J., DELVENNE, P., JERUSALEM, G., Sounni, N. E., & Noël, A. (June 2015). Clinical significance of MT4-MMP and EGFR expression in Breast Cancer [Paper presentation]. Biomedica Life Science Summit, Genk, Belgium. |
Francart, M.-E., Bourcy, M., Lambert, J., Suarez-Carmona, M., Jerusalem, G., Oury, C., Noël, A., & Gilles, C. (13 May 2015). Regulation of Tissue Factor by Epithelial-to-Mesenchymal Transitions: Impacts for the metastatic progression [Poster presentation]. GIGA-Cancer-Day, Liège, Belgium. |
Bourcy, M., Suarez-Carmona, M., Francart, M.-E., Lambert, J., Foidart, J.-M., Jerusalem, G., Noël, A., Oury, C., & Gilles, C. (13 May 2015). Epithelial-to-Mesenchymal Transitions modulate interactions between Circulating Tumor Cells and the coagulation system: implication for the metastatic spread [Paper presentation]. GIGA-Cancer Day, Liège, Belgium. |
Bourcy, M., Suarez-Carmona, M., Francart, M.-E., Lambert, J., Foidart, J.-M., Jerusalem, G., Noël, A., Oury, C., & Gilles, C. (May 2015). Epithelial-to-Mesenchymal Transitions modulate interactions between Circulating Tumor Cells and the coagulation system: implication for the metastatic spread [Poster presentation]. GIGA-Cancer-Day. |
 | Kaufman, P. A., Freyer, G., Kemeny, M., Gonçalves, A., JERUSALEM, G., Stopeck, A., Vrindavanam, N., Dalenc, F., Nanayakkara, N., Wu, B., Pickett, C. A., & Wildiers, H. (May 2015). A phase 1b study of Trebananib plus Paclitaxel and Trastuzumab or Capecitabine and Lapatinib in patients with HER2+ locally recurrent or metastatic breast cancer. Cancer Research, 75 (9), 5-19-14. Peer Reviewed verified by ORBi |
 | JERUSALEM, G., Mariani, G., Ciruelos Gil, E. M., Martin, M., Tjan-Heijnen, V. C., Neven, P., Gavila Gregori, J., Michelotti, A., Montemurro, F., Lang, I., Mardiak, J., Naume, B., Camozzi, M., Lorizzo, K., Brenski, D., & Conte, P. (May 2015). Everolimus in combination with Exemestane in hormone receptor-positive, locally advanced or metastatic breast cancer patients progressing on prior non-steroidal aromatase inhibitors (NSAIs) : BALLET study (CRAD001YIC04). Cancer Research, 75 (9), 5-19-02. Peer Reviewed verified by ORBi |
 | Boukerroucha, M., Josse, C., SEGERS, K., El Guendi, S., FRERES, P., JERUSALEM, G., & Bours, V. (26 March 2015). BRCA1 germline mutation and glioblastoma development: report of cases. BMC Cancer, 15, 181. doi:10.1186/s12885-015-1205-1 Peer Reviewed verified by ORBi |
 | Perez Palacios, A., Blomme, A., Boutry, S., Doumont, G., Sherer, F., Van Simaeys, G., Debois, D., JERUSALEM, G., COLLIGNON, J., DELVENNE, P., DETRY, O., De Pauw, E., Muller, R., Goldman, S., Castronovo, V., & Turtoi, A. (March 2015). Metabolomic, proteomic and preclinical imaging of patient-derived tumor xenografts for improving treatment of liver metastases patients. Acta Gastro-Enterologica Belgica, 78 (1), 134. Peer Reviewed verified by ORBi |
Bourcy, M., Suarez-Carmona, M., Francart, M.-E., Lambert, J., Foidart, J.-M., DELVENNE, P., Jerusalem, G., Noël, A., Oury, C., & Gilles, C. (11 February 2015). Involvement of Epithelial-to-Mesenchymal Transitions on the interactions between Circulating Tumor Cells and the coagulation system: implication for the metastatic spread [Paper presentation]. Journée Télévie, Brussels, Belgium. |
Yip, C., PAYE, A., Truong, A., Cimino, J., COLLIGNON, J., DELVENNE, P., JERUSALEM, G., Sounni, N. E., & Noël, A. (11 February 2015). Clinical significance of MT4-MMP and EGFR expression in Breast Cancer [Paper presentation]. Séminaire des chercheurs Télévie 2015, Bruxelles, Belgium. |
Bourcy, M., Suarez-Carmona, M., Francart, M.-E., Lambert, J., Foidart, J.-M., Delvenne, P., Jerusalem, G., Noël, A., Oury, C., & Gilles, C. (February 2015). Involvement of Epithelial-to-Mesenchymal Transitions on the interactions between Circulating Tumor Cells and the coagulation system: implication for the metastatic spread [Poster presentation]. Télévie's researchers seminar. |
 | NIZET, J.-L., MAWEJA, S., LAKOSI, F., LIFRANGE, E., SCAGNOL, I., SEIDEL, L., Albert, A., & JERUSALEM, G. (February 2015). Oncological and surgical outcome after oncoplastic breast surgery. Acta Chirurgica Belgica, 115, 33-41. doi:10.1080/00015458.2015.11681064 Peer Reviewed verified by ORBi |
Yip, C., PAYE, A., Truong, A., Cimino, J., COLLIGNON, J., DELVENNE, P., JERUSALEM, G., Sounni, N. E., & Noël, A. (31 January 2015). Clinical significance of MT4-MMP and EGFR expression in Breast Cancer [Paper presentation]. ABEC - Tumor Metabolism and Mitochondria, Bruxelles, Belgium. |
 | JERUSALEM, G. (29 January 2015). Do we have to change our anti-cancer strategy in case of cardiac toxicity ? Point of view of the oncologist [Paper presentation]. 34th Annual Congress Belgian Society of Cardiology, Brussels, Belgium. |
Francart, M.-E., Bourcy, M., Suarez-Carmona, M., JERUSALEM, G., Oury, C., & Gilles, C. (27 January 2015). Regulation of Tissue Factor by Epithelial-to-Mesenchymal Transitions: Impacts for the metastatic progression [Poster presentation]. GIGA Day 2015. |
 | Schroyen, S., Adam, S., JERUSALEM, G., & Missotten, P. (2015). Ageism and its clinical impact in oncogeriatry: state of knowledge and therapeutic leads. Clinical Interventions in Aging, 10, 117-125. doi:10.2147/CIA.S70942 Peer Reviewed verified by ORBi |
 | RORIVE, A., EL HAYDERI, L., LIBON, F., DEZFOULIAN, B., JERUSALEM, G., NIKKELS, A., & LEBAS, E. (2015). VISMODEGIB ET CARCINOMES BASOCELLULAIRES LOCALEMENT AVANCES. Revue Médicale de Liège. Peer reviewed |
 | Boukerroucha, M., Josse, C., El Guendi, S., FRERES, P., Marée, R., Wenric, S., SEGERS, K., COLLIGNON, J., JERUSALEM, G., & BOURS, V. (2015). Genetic study of triple negative breast cancers [Poster presentation]. Impakt Breast Cancer Conference, Brussels, Belgium. doi:10.1093/annonc/mdv116.11 |
 | JERUSALEM, G., MOONEN, M., FRERES, P., & LANCELLOTTI, P. (2015). The European Association of Cardiovascular Imaging/Heart Faiture Association Cardiac Oncology Toxicity Registry : long-term benefits for breast cancer treatment. Future Oncology, 11 (20), 2791-2794. doi:10.2217/fon.15.227 Peer Reviewed verified by ORBi |
 | Kelly, K., Patel, M. R., Infante, J. R., Iannotti, N., Nikolinakos, P., Leach, J., Wang, D., Chandler, J. C., JERUSALEM, G., Gurtler, J. S., Arkenau, H.-T., Speit, I., von Heydebreck, A., CHIN, K. M., Heery, C. R., & Gulley, J. L. (2015). Avelumab (MSB0010718C), an anti-PD-L1 antibody, in patients with metastatic or locally advanced solid tumors : assessment of safety and tolerability in a phase I, open-label expansion study. Journal of Clinical Oncology, 33 (suppl ; abstr 3044). Peer Reviewed verified by ORBi |
 | Jerusalem, G., Neven, P., Marinsek, N., Zhang, J., Degun, R., Benelli, G., Saletan, S., Ricci, J.-F., & Andre, F. (2015). Patterns of resource utilization and cost for postmenopausal women with hormone-receptor-positive, human epidermal growth factor receptor-2-negative advanced breast cancer in Europe. BMC Cancer, 15, 787. doi:10.1186/s12885-015-1762-3 Peer Reviewed verified by ORBi |
 | Dieras, V., Wildiers, H., Jassem, J., Dirix, L. Y., Guastalla, J.-P., Bono, P., Hurvitz, S. A., Goncalves, A., Romieu, G., Limentani, S. A., Jerusalem, G., Lakshmaiah, K. C., Roche, H., Sanchez-Rovira, P., Pienkowski, T., Segui Palmer, M. A., Li, A., Sun, Y.-N., Pickett, C. A., & Slamon, D. J. (2015). Trebananib (AMG 386) plus weekly paclitaxel with or without bevacizumab as first-line therapy for HER2-negative locally recurrent or metastatic breast cancer: A phase 2 randomized study. Breast, 24, 182-190. doi:10.1016/j.breast.2014.11.003 Peer reviewed |
 | Jerusalem, G., RORIVE, A., & COLLIGNON, J. (2015). Chemotherapy options for patients suffering from heavily pretreated metastatic breast cancer. Future Oncology, 11 (12), 1775-89. doi:10.2217/fon.15.80 Peer Reviewed verified by ORBi |
 | Schroyen, S., Missotten, P., Marquet, M., Clesse, A., Flamion, A., JERUSALEM, G., & Adam, S. (2015). Le regard (peu optimiste) du soignant sur la personne âgée. Medi-Sphere, 469, 1-3. |
 | Slomian, J., LECLERC, A.-F., Maquet, D., JERUSALEM, G., LIFRANGE, E., COUCKE, P., Bury, T., TOMASELLA, M., Reginster, J.-Y., Bruyère, O., & Crielaard, J.-M. (2015). Prevalence of endocrine therapies that could affect bone health in women following a rehabilitation program after surgery for breast cancer. Osteoporosis International, 26 (S1), 375. Peer Reviewed verified by ORBi |
 | Bovy, N., Blomme, B., Freres, P., Dederen, S., Nivelles, O., Lion, M., Carnet, O., Martial, J., Noël, A., Thiry, M., Jerusalem, G., Josse, C., Bours, V., Tabruyn, S., & Struman, I. (2015). Endothelial exosomes contribute to the antitumor response during breast cancer neoadjuvant chemotherapy via microRNA transfer. Oncotarget. doi:10.18632/oncotarget.3520 Peer Reviewed verified by ORBi |
 | Baitar, A., Kenis, C., Moor, R., Decoster, L., Luce, S., Bron, D., Van Rijswijk, R., Rasschaert, M., Langenaeken, C., Jerusalem, G., Lobelle, J.-P., Flamaing, J., Milisen, K., & Wildiers, H. (2015). Implementation of geriatric assessment-based recommendations in older patients with cancer: A multicentre prospective study. Journal of Geriatric Oncology, 6 (5), 401-10. doi:10.1016/j.jgo.2015.07.005 Peer Reviewed verified by ORBi |
 | JERUSALEM, G., COLLIGNON, J., Josse, C., SCHROEDER, H., RORIVE, A., FRERES, P., LAMBERT, F., KOOPMANSCH, B., PONCIN, A., & BOURS, V. (2015). Cancer du sein : de la thérapie ciblée à la médecine personnalisée. Revue Médicale de Liège, 70 (5-6), 269-276. Peer reviewed |
 | FRERES, P., GONNE, E., COLLIGNON, J., GIOT, J.-B., GENNIGENS, C., & JERUSALEM, G. (2015). Prise en charge de la neutropénie fébrile chez le patient cancéreux. Revue Médicale de Liège, 70 (4), 195-200. Peer reviewed |
 | Plummer, E. R., Verheul, H. M. W., Rottey, S., Leunen, K., JERUSALEM, G., Rolfo, C. D., Nielsen, D. L., Molife, L. R., Kristeleit, R., de Vos-Geelen, J., Mau-Sorensen, M., Soetekouw, P. M. M. B., van Herpen, C., Swaisland, H., Fielding, A., So, K., Bannister, W., & Dirix, L. (2015). Effect of itraconazole and rifampin on the pharmacokinetics of olaparib table formulation in patients with advanced solid tumors : phase I open-label studies. Journal of Clinical Oncology, 33 (suppl : abstr 2565). Peer Reviewed verified by ORBi |
 | Kenis, C., Flamaing, J., Debruyne, P. R., Rasschaert, M., Focan, C., Cornelis, F., Verschaeve, V., Vanoverbeke, K., Libert, Y., Luce, S., Decoster, L., Nols, N., Van den Bulck, H., Goeminne, J.-C., Baitar, A., Geboers, K., Petit, B., Langenaeken, C., Van Rijswijk, R., ... Wildiers, H. (2015). A nationwide implementation of a multidisciplinary geriatric assessment and intervention program in belgian older patients with cancer. Journal of Geriatric Oncology, 6 (S13-S27), 001. Peer Reviewed verified by ORBi |
 | Maris, P., Blomme, A., Palacios, A. P., Costanza, B., Bellahcene, A., BIANCHI, E., GOFFLOT, S., Drion, P., Trombino, G. E., Di Valentin, E., CUSUMANO, G., MAWEJA, S., JERUSALEM, G., Delvenne, P., LIFRANGE, E., Castronovo, V., & Turtoi, A. (2015). Asporin Is a Fibroblast-Derived TGF-beta1 Inhibitor and a Tumor Suppressor Associated with Good Prognosis in Breast Cancer. PLoS Medicine, 12 (9), 1001871. doi:10.1371/journal.pmed.1001871 Peer Reviewed verified by ORBi |
 | COLIN, P.-E., SCHROEDER, H., GONNE, E., Hanocq, F., ANDRE, C., RORIVE, A., Jerusalem, G., & COLLIGNON, J. (2015). BIOPSIE DES LESIONS SUSPECTES CHEZ LES PATIENTS AYANT PRESENTE UN CANCER DU SEIN. Revue Médicale de Liège, 70 (11), 563-8. Peer reviewed |
 | Generali, D., Venturini, S., Rognoni, C., Ciani, O., Pusztai, L., Loi, S., Jerusalem, G., Bottini, A., & Tarricone, R. (2015). A network meta-analysis of everolimus plus exemestane versus chemotherapy in the first- and second-line treatment of estrogen receptor-positive metastatic breast cancer. Breast Cancer Research and Treatment, 152 (1), 95-117. doi:10.1007/s10549-015-3453-9 Peer Reviewed verified by ORBi |
 | SCHROEDER, H., Hanocq, F., COLLIGNON, J., Colin, P.-E., Depuis, Z., Triffaux, F., RORIVE, A., & JERUSALEM, G. (2015). Cancer du sein: intérêt du bilan d’extension par imagerie lors du diagnostic initial et du suivi les trois premières années après le diagnostic. Revue Médicale de Liège, 70 (3), 140-147. Peer reviewed |
 | Plummer, R., Swaisland, H., Leunen, K., van Herpen, C. M. L., JERUSALEM, G., De Grève, J., Lolkema, M. P., Soetekouw, P., Mau-Sorensen, M., Nielsen, D., Spicer, J., Fielding, A., So, K., Bannister, W., & Molife, L. R. (2015). Olaparib tablet formulation : effect of food on the pharmacokinetics after oral dosing in patients with advanced solid tumours. Cancer Chemotherapy and Pharmacology, 76, 723-729. doi:10.1007/s00280-015-2836-2 Peer Reviewed verified by ORBi |
 | Damaraju, S., Gorbunova, V., Gelmon, K. A., Garcia Saenz, J. A., Morales, S., Abigerges, D. Y., Canon, J.-L., Lifirenko, I., Cohen, G. L., JERUSALEM, G., Thireau, F., Fresco, R., Houé, V., Press, M. F., Narasimhan, A., & Mackey, J. R. (2015). Relationship of germline polymorphisms to docetaxel toxicity in the ROSE/TRIO-012 trial. Journal of Clinical Oncology, (suppl abstr 540). Peer Reviewed verified by ORBi |
 | Baitar, A., Kenis, C., Moor, R., Decoster, L., Luce, S., Bron, D., Van Rijswijk, R., Rasschaert, M., Langenaeken, C., JERUSALEM, G., Lobelle, J.-P., Flamaing, J., Milisen, K., & Wildiers, H. (2015). Implementation of geriatric assessment - based recommendations in older patients with cancer : a multicenter prospective study. Journal of Geriatric Oncology, 6, 13-S27. Peer Reviewed verified by ORBi |
 | Slamon, D., Hurvitz, S., Chen, D., Andre, F., Tseng, L.-M., JERUSALEM, G., Wilks, S., O'Regan, R., Isaacs, C., Toi, M., Burris, H., He, W., Riester, M., Robinson, D., Taran, T., & Gianni, L. (2015). Predictive biomarkers of everolimus efficacy in HER2+ advanced breast cancer : combined exploratory analysis from BOLERO-1 and BOLERO-3. Journal of Clinical Oncology, 33 (suppl ; abstr 512). Peer Reviewed verified by ORBi |
 | Lancellotti, P., Anker, S. D., Donal, E., Edvardsen, T., Popescu, B. A., Farmakis, D., Filippatos, G., Habib, G., Maggioni, A. P., Jerusalem, G., & Galderisi, M. (2015). EACVI/HFA Cardiac Oncology Toxicity Registry in breast cancer patients: rationale, study design, and methodology (EACVI/HFA COT Registry)-EURObservational Research Program of the European Society of Cardiology. European Heart Journal. Cardiovascular Imaging. doi:10.1093/ehjci/jev024 Peer Reviewed verified by ORBi |
 | Carnet, O.* , Lecomte, J.* , Masset, A., Primac, I., Durré, T., Maertens, L., Detry, B., Blacher, S., Gilles, C., Péqueux, C., Paupert, J., Foidart, J.-M., Jerusalem, G., Cataldo, D., & Noël, A. (2015). Mesenchymal stem cells shed amphiregulin at the surface of lung carcinoma cells in a juxtacrine manner. Neoplasia, 17 (7), 552-63. doi:10.1016/j.neo.2015.07.002 Peer Reviewed verified by ORBi* These authors have contributed equally to this work. |
 | Boukerroucha, M., Josse, C., El Guendi, S., Boujemla, B., Freres, P., Marée, R., Wenric, S., SEGERS, K., COLLIGNON, J., Jerusalem, G., & Bours, V. (2015). Evaluation of BRCA1-related molecular features and microRNAs as prognostic factors for triple negative breast cancers. BMC Cancer, 15 (1), 755. doi:10.1186/s12885-015-1740-9 Peer Reviewed verified by ORBi |
Schroyen, S., Missotten, P., JERUSALEM, G., GILLES, C., & Adam, S. (16 December 2014). Personnel soignant et âgisme: quelles conséquences cliniques ? [Paper presentation]. 8e congrès de l'Association Francophone de Psychologie de la Santé, Liège, Belgium. |
Bragard, I., Etienne, A.-M., Faymonville, M.-E., Coucke, P., DEVOS, M., LIFRANGE, E., SCHROEDER, H., Wagener, A., Coudert, S., & Jerusalem, G. (16 December 2014). Améliorer le bien-être des patientes atteintes d’un cancer du sein par l’auto-hypnose, le yoga ou la TCC en groupe : faisabilité et premiers résultats au CHU de Liège [Paper presentation]. 8e congrès de l’Association Francophone de Psychologie de la Santé (AFPSA). |
 | Gupta, S., Zhang, J., & JERUSALEM, G. (2014). The association of chemotherapy versus hormonal therapy and health outcomes among patients with hormone receptor-positive, HER2-negative metastatic breast cancer : experience from the patient perspective. Expert Review of Pharmacoeconomics and Outcomes Research. doi:10.1586/14737167.2014.949243 Peer Reviewed verified by ORBi |
 | Schroyen, S., Adam, S., JERUSALEM, G., & Missotten, P. (2014). Double stigmatization influence in oncogeriatry. Psycho-oncology. Peer Reviewed verified by ORBi |
 | Kenis, C., Heeren, P., Bron, D., Decoster, L., Moor, R., Pepersack, T., Langenaeken, C., Rasschaert, M., Jerusalem, G., Van Rijswijk, R., Lobelle, J.-P., Flamaing, J., Milisen, K., & Wildiers, H. (01 October 2014). Multicenter implementation of geriatric assessment in Belgian patients with cancer: A survey on treating physicians' general experiences and expectations. Journal of Geriatric Oncology, 5 (4), 431-438. doi:10.1016/j.jgo.2014.06.043 Peer Reviewed verified by ORBi |
 | Paye, A., Truong, A., Yip, C., Cimino, J., Blacher, S., Munaut, C., Cataldo, D., Foidart, J.-M., Maquoi, E., COLLIGNON, J., Delvenne, P., Jerusalem, G., Noël, A.* , & Sounni, N. E.*. (October 2014). EGFR activation and signaling in cancer cells are enhanced by the membrane-bound metalloprotease MT4-MMP. Cancer Research, 74 (23), 6758-70. doi:10.1158/0008-5472.CAN-13-2994 Peer Reviewed verified by ORBi* These authors have contributed equally to this work. |
Yip, C., PAYE, A., Truong, A., Cimino, J., COLLIGNON, J., DELVENNE, P., JERUSALEM, G., Sounni, N. E., & Noël, A. (30 September 2014). Clinical significance of MT4-MMP and EGFR expression in Breast Cancer [Paper presentation]. Ecole Doctorale Thematique En Cancerologie Experimentale, Liege, Belgium. |
 | JERUSALEM, G. (19 September 2014). Endocrine therapy resistance [Paper presentation]. Câncer de mama - Gramado 2014 - 9e édition, Gramado, Brazil. |
 | JERUSALEM, G. (19 September 2014). Fertility and pregnancy after adjuvant therapy [Paper presentation]. Câncer de mama - Gramado 2014 - 9e édition, Gramado, Brazil. |
Schroyen, S., Missotten, P., JERUSALEM, G., GILLES, C., & Adam, S. (18 September 2014). L'âgisme en oncogériatrie [Paper presentation]. Société francophone d'oncogériatrie. |
 | FRERES, P., JOSSE, C., Bovy, N., Boukerroucha, M., Struman, I., BOURS, V., & JERUSALEM, G. (2014). Neoadjuvant chemotherapy in breast cancer induces miR-34a and miR-122 expression. Journal of Cellular Physiology. doi:10.1002/jcp.24730 Peer Reviewed verified by ORBi |
 | Schroyen, S., Adam, S., JERUSALEM, G., & Missotten, P. (June 2014). Impact de la double stigmatisation en oncogériatrie : Etat des lieux. Gériatrie et Psychologie Neuropsychiatrie du Vieillissement, 12 (2), 131-8. doi:10.1684/pnv.2014.0471 Peer reviewed |
Yip, C., PAYE, A., Truong, A., Cimino, J., COLLIGNON, J., DELVENNE, P., JERUSALEM, G., Sounni, N. E., & Noël, A. (19 May 2014). Clinical significance of MT4-MMP and EGFR expression in Breast Cancer [Paper presentation]. GIGA-Cancer Day 2014, Liege, Belgium. |
Francart, M.-E., Bourcy, M., Suarez-Carmona, M., JERUSALEM, G., Oury, C., & Gilles, C. (19 May 2014). Implication of Epithelial-to-Mesenchymal Transitions (EMTs) on coagulant properties of Circulating Tumor Cells (CTCs): impacts for the metastatic progression [Poster presentation]. GIGA-Cancer Day 2014. |
 | Schroyen, S., Adam, S., JERUSALEM, G., & Missotten, P. (15 May 2014). Etude longitudinale en oncogériatrie: impact de la double stigmatisation [Poster presentation]. Congrès International francophone de Gérontologie et Gériatrie, Liège, Belgium. |
 | JERUSALEM, G., Gupta, S., & Zhang, J. (May 2014). The association of chemotherapy versus hormonal therapy and health outcomes among patients with hormone receptor-positive, HER2-negative metastatic breast cancer: experience from the patient perspective. Value in Health, 17 (3), 95. Peer Reviewed verified by ORBi |
Bourcy, M., Suarez-Carmona, M., Francart, M.-E., Lambert, J., Foidart, J.-M., Delvenne, P., Jerusalem, G., Noël, A., Oury, C., & Gilles, C. (May 2014). Epithelial-to-Mesenchymal Transitions modulate interactions between Circulating Tumor Cells and the coagulation system: implication for the metastatic spread [Poster presentation]. GIGA-Cancer-Day. |
 | JERUSALEM, G. (24 April 2014). Mechanisms of endocrine resistance and how to overcome them ? Taking advantage of the cross talk at the clinical level [Paper presentation]. IX Santiago International Breast Cancer Symposium, Santiago, Chile. |
 | JERUSALEM, G. (24 April 2014). Selecting the neoadjuvant treatment by molecular subtype : How to maximize the benefits [Paper presentation]. IX Santiago International Breast Cancer Symposium, Santiago, Chile. |
 | JERUSALEM, G. (24 April 2014). Extended adjuvant endocrine therapy. Who benefits ? For how long ? [Paper presentation]. IX Santiago International Breast Cancer Symposium, Santiago, Chile. |
 | JERUSALEM, G. (21 March 2014). This house believes that 5 or fewer years of adjuvant endocrine therapy is insufficient [Paper presentation]. 9th European Breast Cancer Conference, Glasgow, United Kingdom. |
 | JERUSALEM, G. (22 February 2014). New chemotherapy drugs in metastatic breast cancer [Paper presentation]. Innovation in breast cancer - IBC 2014, Madrid, Spain. |
Yip, C., PAYE, A., Truong, A., Cimino, J., COLLIGNON, J., DELVENNE, P., JERUSALEM, G., Sounni, N. E., & Noël, A. (27 January 2014). Study of the pro-tumoral effects of MT4-MMP [Paper presentation]. GIGA-Day 2014, Liege, Belgium. |
 | JERUSALEM, G., Gupta, S., & Zhang, J. (2014). The association of chemotherapy versus hormonal therapy and health outcomes by geographic region among patients with hormone receptor-positive, HER2-negative metastatic breast cancer : experience from the patient perspective [Poster presentation]. 9th European Breast Cancer Conference, Glasgow, United Kingdom. |
 | Cusumano, P. G., Generali, D., Ciruelos, E., Manso, L., Ghanem, I., LIFRANGE, E., Jerusalem, G., Klaase, J., de Snoo, F., Stork-Sloots, L., Dekker-Vroling, L., & Lutke Holzik, M. (2014). European inter-institutional impact study of MammaPrint. Breast, 23 (4), 423-8. doi:10.1016/j.breast.2014.02.011 Peer reviewed |
 | Plana, J. C., Galderisi, M., Barac, A., Ewer, M. S., Ky, B., Scherrer-Crosbie, M., Ganame, J., Sebag, I. A., Agler, D. A., Badano, L. P., Banchs, J., Cardinale, D., Carver, J., Cerqueira, M., DeCara, J. M., Edvardsen, T., Flamm, S. D., Force, T., Griffin, B. P., ... Lancellotti, P. (2014). Expert consensus for multimodality imaging evaluation of adult patients during and after cancer therapy: a report from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. European Heart Journal. Cardiovascular Imaging, 15 (10), 1063-93. doi:10.1093/ehjci/jeu192 Peer Reviewed verified by ORBi |
 | Plana, J. C., Galderisi, M., Barac, A., Ewer, M. S., Ky, B., Scherrer-Crosbie, M., Ganame, J., Sebag, I. A., Agler, D. A., Badano, L. P., Banchs, J., Cardinale, D., Carver, J., Cerqueira, M., DeCara, J. M., Edvardsen, T., Flamm, S. D., Force, T., Griffin, B. P., ... Lancellotti, P. (2014). Expert Consensus for Multimodality Imaging Evaluation of Adult Patients during and after Cancer Therapy: A Report from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. Journal of the American Society of Echocardiography, 27 (9), 911-39. doi:10.1016/j.echo.2014.07.012 Peer Reviewed verified by ORBi |
 | Andre, F., Neven, P., Marinsek, N., Zhang, J., Baladi, J.-F., Degun, R., Benelli, G., Saletan, S., & Jerusalem, G. (2014). Disease management patterns for postmenopausal women in Europe with hormone-receptor-positive, human epidermal growth factor receptor-2 negative advanced breast cancer. Current Medical Research and Opinion. doi:10.1185/03007995.2014.887002 Peer Reviewed verified by ORBi |
 | Saura, C., Bendell, J., Jerusalem, G., Su, S., Ru, Q., De Buck, S., Mills, D., Ruquet, S., Bosch, A., Urruticoechea, A., Beck, J. T., Di Tomaso, E., Sternberg, D. W., Massacesi, C., Hirawat, S., Dirix, L., & Baselga, J. (2014). Phase Ib study of Buparlisib plus Trastuzumab in patients with HER2-positive advanced or metastatic breast cancer that has progressed on Trastuzumab-based therapy. Clinical Cancer Research, 20 (7), 1935-45. doi:10.1158/1078-0432.CCR-13-1070 Peer Reviewed verified by ORBi |
 | Schroyen, S., Adam, S., Jerusalem, G., & Missotten, P. (2014). L'âgisme et ses conséquences cliniques en oncogériatrie: état des lieux et pistes d'interventions. Revue Médicale de Liège, 69 (5-6), 395-401. Peer reviewed |
 | Jerusalem, G., Bachelot, T., Barrios, C., Neven, P., Di Leo, A., Janni, W., & de Boer, R. (2014). A new era of improving progression-free survival with dual blockade in postmenopausal HR, HER2 advanced breast cancer. Cancer Treatment Reviews. doi:10.1016/j.ctrv.2014.12.011 Peer Reviewed verified by ORBi |
 | Leo, A. D., Jerusalem, G., Petruzelka, L., Torres, R., Bondarenko, I. N., Khasanov, R., Verhoeven, D., Pedrini, J. L., Smirnova, I., Lichinitser, M. R., Pendergrass, K., Malorni, L., Garnett, S., Rukazenkov, Y., & Martin, M. (2014). Final Overall Survival: Fulvestrant 500 mg vs 250 mg in the Randomized CONFIRM Trial. Journal of the National Cancer Institute, 106 (1), 337. doi:10.1093/jnci/djt337 Peer Reviewed verified by ORBi |
 | Bonnefoi, H., Jacot, W., Saghatchian, M., Moldovan, C., Venat-Bouvet, L., Zaman, K., Matos, E., Petit, T., Bodmer, A., Quenel-Tueux, N., Chakiba, C., Vuylsteke, P., Jerusalem, G., Brain, E., Tredan, O., Messina, C. G. M., Slaets, L., & Cameron, D. (2014). Neoadjuvant treatment with docetaxel plus lapatinib, trastuzumab, or both followed by an anthracycline based chemotherapy in HER2-positive breast cancer: results of the randomised phase II EORTC 10054 study. Annals of Oncology. doi:10.1093/annonc/mdu551 Peer Reviewed verified by ORBi |
 | Bragard, I., Etienne, A.-M., Faymonville, M.-E., Coucke, P., DEVOS, M., LIFRANGE, E., SCHROEDER, H., Wagener, A., & Jerusalem, G. (2014). Self-hypnosis, yoga or CBT group to face breast cancer: feasibility study and first results in Belgium. Psycho-oncology, 23 (suppl 3), 174. Peer Reviewed verified by ORBi |
 | Duray, A., Demoulin, S., Petermans, J., Moutschen, M., Saussez, S., Jerusalem, G., & Delvenne, P. (2014). Vieillissement et cancer: coincidence ou relation etiologique? Revue Médicale de Liège, 69 (5-6), 276-81. Peer reviewed |
 | Jerusalem, G., RORIVE, A., & COLLIGNON, J. (2014). Use of mTOR inhibitors in the treatment of breast cancer: an evaluation of factors that influence patient outcomes. Breast Cancer, 6, 43-57. doi:10.2147/BCTT.S38679 Peer Reviewed verified by ORBi |
 | BARTHELEMY, N., LENNERTS, E., MEYNS, M., DUYSINX, B., PAULUS, A., COMPERE, C., BOSQUEE, L., JERUSALEM, G., & COUCKE, P. (2014). LE DÉFI DU CONTRÔLE LOCAL DANS LE CANCER PULMONAIRE NON A PETITES CELLULES, LOCALEMENT AVANCE, NON OPERABLE. Revue Médicale de Liège, 69 (Supp 1), 75-80. Peer reviewed |
 | Coleman, R., Aksnes, A.-K., Naume, B., Garcia, C., Jerusalem, G., Piccart, M., Vobecky, N., Thuresson, M., & Flamen, P. (2014). A phase IIa, nonrandomized study of radium-223 dichloride in advanced breast cancer patients with bone-dominant disease. Breast Cancer Research and Treatment. doi:10.1007/s10549-014-2939-1 Peer Reviewed verified by ORBi |
 | Andre, F., O'Regan, R., Ozguroglu, M., Toi, M., Xu, B., Jerusalem, G., Masuda, N., Wilks, S., Arena, F., Isaacs, C., Yap, Y.-S., Papai, Z., Lang, I., Armstrong, A., Lerzo, G., White, M., Shen, K., Litton, J., Chen, D., ... Gianni, L. (2014). Everolimus for women with trastuzumab-resistant, HER2-positive, advanced breast cancer (BOLERO-3): a randomised, double-blind, placebo-controlled phase 3 trial. The Lancet Oncology. doi:10.1016/S1470-2045(14)70138-X Peer Reviewed verified by ORBi |
 | JERUSALEM, G., RORIVE, A., & COLLIGNON, J. (2014). Le médicament du mois : Everolimus (Afinitor) dans le traitement du cancer du sein métastatique. Revue Médicale de Liège, 69 (9), 510-517. Peer reviewed |
 | BARTHELEMY, N., GENNIGENS, C., Scholtes, F., TSHIBANDA, L., OTTO, B., PIRET, P., MARTIN, D., JERUSALEM, G., & COUCKE, P. (2014). Le traitement multidisciplinaire du glioblastome. Revue Médicale de Liège, 69, 63-68. Peer reviewed |
 | Wenric, S., Freres, P., Josse, C., Bours, V., & Jerusalem, G. (09 December 2013). A miRNA expression based diagnostic tool for breast cancer using random forests [Poster presentation]. Benelux Bioinformatics Conference 2013. |
Yip, C., PAYE, A., Truong, A., Cimino, J., COLLIGNON, J., DELVENNE, P., Jerusalem, G., Sounni, N. E., & Noël, A. (05 December 2013). Study of the pro-tumoral effects of MT4-MMP [Paper presentation]. Séminaire des chercheurs Télévie 2014, Bruxelles, Belgium. |
 | Isaacs, C., Ozguroglu, M., JERUSALEM, G., Xu, B., Lang, I., O'Regan, R., White, M., Fasolo, A., Litton, J., Toi, M., Shen, K., André, F., Vuylsteke, P., Zhang, Y., Zhang, J., Taran, T., & Wilks, S. (December 2013). BOLERO-3 : Quality-of-life maintained in patients with HER-2 positive metastatic breast cancer treated with Everolimus plus Trastuzumab plus Vinorelbine. Cancer Research, 73 (24), 4-12-18. Peer Reviewed verified by ORBi |
 | Toi, M., Masuda, N., ANDRE, F., Ishiguro, H., Fasolo, A., Xu, B., JERUSALEM, G., Shen, K., Wilks, S., O'Regan, R., Isaacs, C., Zhang, Y., Taran, T., & Yap, Y.-S. (December 2013). BOLERO-3 : Everolimus plus Trastuzumab and Vinorelbine in asian patients with HER2-positive metastatic breast cancer. Cancer Research, 73 (24), 4-12-19. Peer Reviewed verified by ORBi |
 | Gennari, A., JERUSALEM, G., & Maibach, R. (December 2013). The SNAP trial : schedules of nab-Paclitaxel in metastatic breast cancer. International breast cancer study group (ICGSG 42-12) and breast international group (BIG 2-12). Cancer Research, 73 (24), 3-1-02. Peer Reviewed verified by ORBi |
 | JERUSALEM, G., Masuda, N., Andre, F., Fein, L., Fasolo, A., O'Regan, R., Wilks, S., Isaacs, C., Zhang, Y., Taran, T., & Toi, M. (December 2013). Safety analysis of BOLERO-3 : a phase III trial of daily Everolimus vs placebo, both with weekly Trastuzumab and Vinorelbine in Trastuzumab-resistant, advanced breast cancer. Cancer Research, 73 (24), 3-15-03. Peer Reviewed verified by ORBi |
 | Schroyen, S., Adam, S., JERUSALEM, G., & Missotten, P. (16 November 2013). Etude longitudinale en oncogériatrie: impact de la double stigmatisation [Poster presentation]. 40 èmes Journées Scientifiques de l'Association pour l'Etude, la Modification et la Thérapie du Comportement, Liège, Belgium. |
 | Martin, L.-A., Andre, F., Campone, M., Bachelot, T., & JERUSALEM, G. (November 2013). mTOR inhibitors in advanced breast cancer: ready for prime time? Cancer Treatment Reviews, 39 (7), 742-52. doi:10.1016/j.ctrv.2013.02.005 Peer Reviewed verified by ORBi |
 | de Boer, R., JERUSALEM, G., Hurvitz, S., Ejlertsen, B., El-Hashimy, M., Feng, W., Taran, T., & Burris, H. (November 2013). Efficacy and safety of Everolimus plus Exemestane combinaison therapy versus monotherapy with Everolimus or Capecitabine in HR+, HER2- breast cancer : a multicenter, open-label, phase 2 trial BOLERO-6. Breast, 22 (3). Peer reviewed |
Yip, C., PAYE, A., Truong, A., Cimino, J., COLLIGNON, J., DELVENNE, P., JERUSALEM, G., Sounni, N. E., & Noël, A. (13 September 2013). Study of the pro-tumoral effects of MT4-MMP [Paper presentation]. Annual Mini Symposium 2013, Liege, Belgium. |
 | JERUSALEM, G., ANDRE, F., CHEN, D., ROBINSON, D., OZGUROGLU, M., LANG, I., WHITE, M., TOI, M., TARAN, T., & GIANNI, L. (September 2013). Evaluation of Everolimus (EVE) in HER2+ advanced breast cancer (BC) with activated PI3K/mTOR pathway : exploratory biomarker observations from the BOLERO-3 trial. European Journal of Cancer, 49 (Supplement 3), 8. Peer Reviewed verified by ORBi |
Yip, C., PAYE, A., Truong, A., Cimino, J., COLLIGNON, J., DELVENNE, P., JERUSALEM, G., Sounni, N. E., & Noël, A. (02 July 2013). Regulation of breast cancer cell properties by MT4-MMP [Paper presentation]. Mini symposium "Tumor Microenvironment", Liege, Belgium. |
Yip, C., PAYE, A., Truong, A., Cimino, J., COLLIGNON, J., DELVENNE, P., JERUSALEM, G., Sounni, N. E., & Noël, A. (17 May 2013). Regulation of breast cancer cell properties by MT4-MMP [Paper presentation]. GIGA-Cancer Day 2013. |
 | Wenric, S., JOSSE, C., Fasquelle, C., Poulet, C., Sticca, T., Boukerroucha, M., JERUSALEM, G., & Bours, V. (15 March 2013). Exome sequencing of tumors: relevance in copy-number alteration (CNA) analysis and fixed tissue samples [Poster presentation]. 13th Annual Meeting of the Belgian Society of Human Genetics, Bruxelles, Belgium. |
 | Vanderhaegen, J., Paridaens, R., Piccart, M., Lalami, Y., Machiels, J., JERUSALEM, G., Borms, M., Goeminne, J., Mebis, J., Dirix, L., De Greve, J., Berteloot, P., Lintermans, A., Brouckaert, O., & Neven, P. (March 2013). The 2006 adjuvant Trastuzumab convention in Belgium: 5 years later [Poster presentation]. 13th St Gallen International Breast Cancer Conference 2013, Saint-Gallen, Switzerland. |
 | Ejlertsen, B., JERUSALEM, G., Hurvitz, S., de Boer, R., Taran, T., Sahmoud, T., & Burris, H. (March 2013). Everolimus Plus Exemestane Versus Everolimus or Capecitabine Monotherapy in Breast Cancer : BOLERO-6 [Poster presentation]. St. Gallen International Breast Cancer Conference, St Gallen, Switzerland. |
Yip, C., PAYE, A., Truong, A., Cimino, J., COLLIGNON, J., DELVENNE, P., JERUSALEM, G., Sounni, N. E., & Noël, A. (29 January 2013). Regulation of breast cancer cell properties by MT4-MMP [Paper presentation]. GIGA-Day 2013, Liege, Belgium. |
Yip, C., PAYE, A., Truong, A., Cimino, J., COLLIGNON, J., DELVENNE, P., JERUSALEM, G., Sounni, N. E., & Noël, A. (29 January 2013). Regulation of breast cancer cell properties by MT4-MMP [Paper presentation]. EDT cancérologie. |
 | Benoit, A., Jerusalem, G., & GENNIGENS, C. (2013). Le cas clinique du mois. Métastase musculaire en présence d'un cancer de l'ovaire. Revue Médicale de Liège, 68 (11), 557-61. Peer reviewed |
 | Awada, A., Garcia, A. A., Chan, S., JERUSALEM, G., Coleman, R. E., Huizing, M. T., Mehdi, A., O'Reilly, S. M., Hamm, J. T., Barrett-Lee, P. J., Cocquyt, V., Sideras, K., Young, D. E., Zhao, C., Chia, Y. L., Hoch, U., Hannah, A. L., & Perez, E. A. (2013). Two schedules of etirinotecan pegol (NKTR-102) in patients with previously treated metastatic breast cancer: a randomised phase 2 study. The Lancet Oncology, 14 (12), 1216-1225. doi:10.1016/S1470-2045(13)70429-7 Peer Reviewed verified by ORBi |
 | Flamen, P., Coleman, R., Naume, B., JERUSALEM, G., Garcia, C., Aksnes, A.-K., & Piccart, M. (2013). 18F-FDG PET : Changes in uptake as a method to assess radium-223 dichloride (Ra-223) response in bone metastases of breast cancer patients with bone-dominant disease. Journal of Nuclear Medicine, 54 (supplement 2), 647. Peer Reviewed verified by ORBi |
 | Bachelot, T., McCool, R., Duffy, S., Glanville, J., Varley, D., Fleetwood, K., Zhang, J., & Jerusalem, G. (2013). Comparative efficacy of everolimus plus exemestane versus fulvestrant for hormone-receptor-positive advanced breast cancer following progression/recurrence after endocrine therapy: a network meta-analysis. Breast Cancer Research and Treatment. doi:10.1007/s10549-013-2778-5 Peer Reviewed verified by ORBi |
 | Garnett, S. A., Martin, M., JERUSALEM, G., Petruzelka, L., Torres, R., Bondarenko, I. N., Khasanov, R., Verhoeven, D., Pedrini, J. L., Smirnova, I., Lichinitser, M. R., Pendergrass, K., Lindemann, J. P. O., & Di Leo, A. (2013). Comparing duration of response and duration of clinical benefit between fulvestrant treatment groups in the CONFIRM trial: application of new methodology. Breast Cancer Research and Treatment, 138 (1), 149-55. doi:10.1007/s10549-012-2395-8 Peer Reviewed verified by ORBi |
 | Beyaert, R., Beaugerie, L., Van Assche, G., Brochez, L., Renauld, J.-C., Viguier, M., Cocquyt, V., JERUSALEM, G., Machiels, J.-P., Prenen, H., Masson, P., Louis, E., & De Keyser, F. (2013). Cancer risk in immune-mediated inflammatory diseases (IMID). Molecular Cancer, 12 (1), 98. doi:10.1186/1476-4598-12-98 Peer Reviewed verified by ORBi |
 | Senkus, E., Gomez, H., Dirix, L., JERUSALEM, G., Murray, E., Van Tienhoven, G., Westenberg, A. H., Bottomley, A., Rapion, J., Bogaerts, J., Di Leo, A., & Neskovic-Konstantinovic, Z. (2013). Attitudes of young patients with breast cancer toward fertility loss related to adjuvant systemic therapies. EORTC study 10002 BIG 3-98. Psycho-oncology. doi:10.1002/pon.3384 Peer Reviewed verified by ORBi |
 | Ejlerstsen, B., JERUSALEM, G., Hurvitz, S., de Boer, R., Taran, T., Sahmoud, T., & Burris, H. (2013). Bolero-6:Phase 2 Study of Everolimus plus Exemestane versus Everolimus or Capecitabine Monotherapy in HR+HER2- Advanced Breast Cancer. Journal of Clinical Oncology, 31, 660. Peer Reviewed verified by ORBi |
 | DI LEO, A., JERUSALEM, G., PETRUZELKA, L., TORRES, R., BONDARENKO, I. N., KHASANOV, R., VERHOEVEN, D., PEDRINI, J. L., SMIRNOVA, I., LICHINITSER, M. R., PENDERGRASS, K., GARNETT, S., RUKAZENKOV, Y., & MARTIN, M. (15 December 2012). Final analysis of overall survival for the Phase III CONFIRM trial: fulvestrant 500 mg versus 250 mg. Cancer Research. Supplement, 72 (24), 1-4. Peer reviewed |
Yip, C., PAYE, A., Truong, A., Cimino, J., COLLIGNON, J., DELVENNE, P., JERUSALEM, G., Sounni, N. E., & Noël, A. (10 December 2012). Regulation of breast cancer cell properties by MT4-MMP [Paper presentation]. Séminaire des chercheurs Télévie 2013, Liege, Belgium. |
Yip, C., PAYE, A., Truong, A., Cimino, J., COLLIGNON, J., DELVENNE, P., JERUSALEM, G., Sounni, N. E., & Noël, A. (09 November 2012). Regulation of breast cancer cell properties by MT4-MMP [Paper presentation]. Fall meeting of the belgian society for biochemistry and molecular biology - "Metabolomics... To Do What?", Namur, Belgium. |
 | ANDRE, F., MARINSEK, N., RICCI, J.-F., ETCHBERGER, J., DEGUN, R., BENELLI, G., SALETAN, S., & JERUSALEM, G. (November 2012). Patterns of Clinical Management and Resource Utilisation for Postmenopausal Hormone-Receptor-Positive HER2-Negative (HR+ HER2-) Advanced Breast Cancer (BC) in Europe. Value in Health, 15 (7), 419. Peer Reviewed verified by ORBi |
 | Marchal, N., GENNIGENS, C., & JERUSALEM, G. (November 2012). Carcinomatose péritonéale d'origine indéterminée. Revue Médicale de Liège, 67 (11), 582-586. Peer reviewed |
Yip, C., PAYE, A., Truong, A., Cimino, J., COLLIGNON, J., DELVENNE, P., JERUSALEM, G., Sounni, N. E., & Noël, A. (13 October 2012). Regulation of breast cancer cell properties by MT4-MMP [Paper presentation]. Fall meeting of the belgian society for cell and developmental biology - epidermal cell biology, Namur, Belgium. |
 | CUSUMANO, G., Generali, D., Ciruelos, E., Manso, L., Ghanem, I., LIFRANGE, E., JERUSALEM, G., Klaase, J., Stork-Sloots, L., & Lutke Holzik, M. (2012). European inter-institutional impact study of MammaPrint [Poster presentation]. ESMO 2012 Congress Vienna, Vienna, Austria. |
 | JERUSALEM, G., MARINSEK, N., RICCI, J.-F., ETCHBERGER, J., DEGUN, R., BENELLI, G., SALETAN, S., & ANDRE, F. (2012). Clinical Management and Resource Utilisation for Postmenopausal Hormone-Receptor-Positive HER2-Negative (HR+ HER2-) Advanced Breast Cancer (BC) in Europe [Poster presentation]. 2012 ESMO congress, Vienne, Austria. |
 | COLLIGNON, J., & JERUSALEM, G. (2012). Les traitements cibles remplaceront-ils la chimiotherapie? Revue Médicale de Liège, 67 Spec No, 29-36. Peer reviewed |
 | Llombart, A., Frassoldati, A., Paija, O., Sleeboom, H. P., JERUSALEM, G., Mebis, J., Deleu, I., Miller, J., Schenk, N., & Neven, P. (2012). Immediate Administration of Zoledronic Acid Reduces Aromatase Inhibitor-Associated Bone Loss in Postmenopausal Women With Early Breast Cancer: 12-month analysis of the E-ZO-FAST trial. Clinical Breast Cancer, 12 (1), 40-8. Peer Reviewed verified by ORBi |
 | Coudert, B., Asselain, B., Campone, M., Spielmann, M., Machiels, J.-P., Penault-Llorca, F., Serin, D., Levy, C., Romieu, G., Canon, J.-L., Orfeuvre, H., Piot, G., Petit, T., JERUSALEM, G., Audhuy, B., Veyret, C., Beauduin, M., Eymard, J.-C., Martin, A.-L., & Roche, H. (2012). Extended Benefit from Sequential Administration of Docetaxel after Standard Fluorouracil, Epirubicin, and Cyclophosphamide Regimen for Node-Positive Breast Cancer: The 8-Year Follow-Up Results of the UNICANCER-PACS01 Trial. Oncologist, 17 (7), 900-909. doi:10.1634/theoncologist.2011-0442 Peer Reviewed verified by ORBi |
 | GENNIGENS, C., & JERUSALEM, G. (2012). Pazopanib (Votrient) dans le traitement du cancer du rein et des sarcomes des tissus mous. Revue Médicale de Liège, 67 (7-8), 437-42. Peer reviewed |
 | VANDERHAEGEN, J., PARIDAENS, R., PICCART, M., LALAMI, Y., Machiels, J., JERUSALEM, G., BORMS, M., GOEMINNE, J., MEBIS, J., DIRIX, L., LINTERMANS, A., BROUCKAERT, O., & NEVEN, P. (2012). The 2006 Adjuvant Trastuzumab Convention in Belgium: 5 years later. Cancer Research, 5-18-19. Peer Reviewed verified by ORBi |
 | Pistilli, B., Urruticoechea, A., Chan Stephen, Han, H. S., JERUSALEM, G., Kong, A., Ru, Q., Ruquet, S., Sternberg, D., & Saura, C. (2012). Ph Ib/II study of BKM120 plus trastuzumab in patients with trastuzumab-resistant HER2+ advanced breast cancer. Annals of Oncology, 23 (supplément 9), 116. Peer Reviewed verified by ORBi |
 | MARTIN, M., COLLIGNON, J., RORIVE, A., ANDRE, C., BOURHABA, M., ALLEPAERTS, S., COUCKE, P., LIFRANGE, E., & JERUSALEM, G. (2011). Le cancer du sein de la femme âgée. Revue Médicale de Liège, 66 (5-6), 400-408. Peer reviewed |
 | COLLIGNON, J., RORIVE, A., MARTIN, M., ANDRE, C., MAWEJA, S., LIFRANGE, E., COUCKE, P., & JERUSALEM, G. (2011). Chimiothérapie et cancer du sein. Revue Médicale de Liège, 66 (5-6), 372-378. Peer reviewed |
 | RORIVE, A., COLLIGNON, J., MARTIN, M., ANDRE, C., JERUSALEM, G., & COUCKE, P. (2011). Cancer du sein et métastases cérébrales. Revue Médicale de Liège, 66 (5-6), 299-305. Peer reviewed |
 | LIFRANGE, E., ANDRE, C., BLERET, V., COLLIGNON, J., COUCKE, P., CUSUMANO, G., DESREUX, J., HERMAN, P., JERUSALEM, G., KRIDELKA, F., MARTIN, M., RORIVE, A., Van Cauwenberge, J.-R., & COLIN, C. (2011). Hormonothérapie du cancer du sein. Revue Médicale de Liège, 66 (5-6), 367-371. Peer reviewed |
 | COLLIGNON, J., Struman, I., Tabruyn, S., Josse, C., Boukerroucha, M., JERUSALEM, G., & BOURS, V. (2011). Aspects moléculaires du cancer du sein triple négatif et les implications thérapeutiques. Revue Médicale de Liège, 66 (5-6), 393-396. Peer reviewed |
 | JERUSALEM, G., & COUCKE, P. (2011). Apport de la consultation oncologique multidisciplinaire dans le choix des options thérapeutiques. Revue Médicale de Liège, 66 (5-6), 311-314. Peer reviewed |
 | COUCKE, P., JANSEN, N., JANVARY, Z. L., LOUIS, C., VANDERICK, J., RORIVE, A., COLLIGNON, J., LIFRANGE, E., MAWEJA, S., & JERUSALEM, G. (2011). Accelerated partial breast irradiation: state of the art. Belgian Journal of Medical Oncology, 5 (1), 3-7. Peer Reviewed verified by ORBi |
 | Dieras, V., Jassem, J., Dirix, L. Y., Guastalla, J. P., Bono, P., Hurvitz, S. A., Gonçalves, A., Romieu, G., Limentani, S. A., JERUSALEM, G., Lakshmaiah, K., Roche, H. H., Sanchez-Rovira, P., Pienkowski, T., Segui-Palmer, M. A., Li, A., Sun, Y., Pickett-Gies, C. A., & Wildiers, H. (2011). A randomized, placebo-controlled phase II study of AMG 386 plus bevacizumab (Bev) and paclitaxel (P) or AMG 386 plus P as first-line therapy in patients (pts) with HER2-negative, locally recurrent or metastatic breast cancer (LR/MBC). Journal of Clinical Oncology, 29. Peer Reviewed verified by ORBi |
 | WITHOFS, N., COLLIGNON, J., RORIVE, A., JERUSALEM, G., & HUSTINX, R. (2011). Hétérogénéité des métastases osseuses du cancer du sein : cas clinique illustrant l'intérêt de combiner différentes techniques d'imagerie. Revue Médicale de Liège, 66 (5-6), 288-290. Peer reviewed |
 | Awada, A., Chan, S., JERUSALEM, G., Coleman, R. E., Huizing, M. T., Mehdi, A., O'Reilly, S. M., Hamm, J. T., Barrett-Lee, P. J., Cocquyt, V., Sideras, K., Young, D. E., Brown, M., Zhao, C., Hannah, A. L., Masuoka, L. K., Garcia, A., & Perez, E. A. (2011). Antitumor activity in a randomized phase II study comparing two schedules of NKTR-102 in patients (Pts) with pretreated metastatic breast cancer (MBC). Journal of Clinical Oncology, 29. Peer Reviewed verified by ORBi |
 | Gilles, C., COLLIGNON, J., Noël, A., Jerusalem, G., & Foidart, J.-M. (2011). Cellules Tumorales Circulantes : détection, caractérisation et intérêts cliniques. Revue Médicale de Liège, 66 (5-6), 279-84. Peer reviewed |
 | COUCKE, P., LAKOSI, F., RORIVE, A., JANVARY, Z. L., COLLIGNON, J., JANSEN, N., ANDRE, C., & JERUSALEM, G. (2011). Radiothérapie et cancer du sein : "standards" de traitement, prédiction de rechute locale et questions ouvertes. Revue Médicale de Liège, 66 (5-6), 320-325. Peer reviewed |
 | LIFRANGE, E., ANDRE, C., BLERET, V., BRADFER, J., CRISTINELLI, S., COUCKE, P., CUSUMANO, G., FRIDMAN, V., JERUSALEM, G., MARION, F., & COLIN, C. (2011). Prise en charge et suivi d'une série consécutive de 411 patientes opérées pour cancer du sein. Revue Médicale de Liège, 66 (5-6), 329-335. Peer reviewed |
 | JERUSALEM, G., COLLIGNON, J., RORIVE, A., LIFRANGE, E., ANDRE, C., MARTIN, M., MAWEJA, S., & COUCKE, P. (2011). Traitements ciblés dans le cancer du sein. Revue Médicale de Liège, 66 (5-6), 379-384. Peer reviewed |
 | Withofs, N., Grayet, B., Tancredi, T., Rorive, A., Mella, C., Giacomelli, F., Mievis, F., Aerts, J., Waltregny, D., Jerusalem, G., & Hustinx, R. (2011). 18F-fluoride PET/CT for assessing bone involvement in prostate and breast cancers. Nuclear Medicine Communications, 32 (3), 168-176. doi:10.1097/MNM.0b013e3283412ef5 Peer Reviewed verified by ORBi |
 | GENNIGENS, C., & Jerusalem, G. (2011). Trabectedine (ET-743/Yondelis) dans le traitement des sarcomes des tissus mous et du cancer de l'ovaire. Revue Médicale de Liège, 66 (7-8), 452-5. Peer reviewed |
 | Jerusalem, G., Fasolo, A., Dieras, V., Cardoso, F., Bergh, J., Vittori, L., Zhang, Y., Massacesi, C., Sahmoud, T., & Gianni, L. (January 2011). Phase I trial of oral mTOR inhibitor everolimus in combination with trastuzumab and vinorelbine in pre-treated patients with HER2-overexpressing metastatic breast cancer. Breast Cancer Research and Treatment, 125 (2), 447-455. doi:10.1007/s10549-010-1260-x Peer Reviewed verified by ORBi |
 | ANDRE, C., COLLIGNON, J., RORIVE, A., MARTIN, M., MAWEJA, S., LIFRANGE, E., COUCKE, P., & JERUSALEM, G. (2011). Le cancer du sein chez la femme jeune. Revue Médicale de Liège, 66 (5-6), 397-399. Peer reviewed |
 | LOUSBERG, L., SOMJA, J., COLLIGNON, J., Gilles, C., & JERUSALEM, G. (2011). A propos d'un cas de rechute tardive de cancer du sein après traitement adjuvant. Revue Médicale de Liège, 66 (5-6), 306-310. Peer reviewed |
 | Garcia, A., Awada, A., Chan, S., JERUSALEM, G., Coleman, R. E., Huizing, M. T., Mehdi, A., O'Reilly, S. M., Hamm, J. T., Barrett-Lee, P. J., Cocquyt, V., Sideras, K., Young, D. E., Brown, M., Zhao, C., Hannah, A. L., Leung, A. C. F., Masuoka, L. K., & Perez, E. A. (2011). Final results of NKTR-102, a topoisomerase I inhibitor-polymer conjugate, in patients (Pts) with pretreated metastatic breast cancer (MBC) demonstrating significant antitumor activity. Journal of Clinical Oncology, 29 (supplement 27). Peer Reviewed verified by ORBi |
 | JERUSALEM, G., & SCHEEN, A. (2011). Editorial. Le cancer du sein. Revue Médicale de Liège, 66 (5-6), 225-228. Peer reviewed |
 | Awada, A., Chan, S., JERUSALEM, G., Coleman, R. E., Huizing, M., Mehdi, A., O'Reilly, S. M., Hamm, J. T., Patel, T., Hannah, A. L., Masuoka, L. K., Garcia, A. A., & Perez, E. A. (December 2010). Significant efficacy in a phase 2 study of NKTR-102, a novel polymer conjugate of Irinotecan, in patients with pre-treated metastatic breast cancer (MBC). Cancer Research, 70 (24), 6-11-01. Peer Reviewed verified by ORBi |
 | Nechushtan, H., Edelman, G., JERUSALEM, G., Gordon, M., Kluger, H., Moussa, A., Ron, I., Schimmoller, F., Shen, X., & Daud, A. (November 2010). Phase 2 Results of XL184 in a Cohort of Patients with Advanced Melanoma. EJC Supplements, 8 (7), 126-127. Peer Reviewed verified by ORBi |
 | Collignon, J., Gennigens, C., & Jerusalem, G. (July 2010). Assessment of Response to Therapy for Bone Metastases : Is it still a challenge in oncology ? PET Clinics, 5 (3), 311-326. doi:10.1016/j.cpet.2010.05.002 Peer Reviewed verified by ORBi |
 | Freres, P., Collignon, J., Gennigens, C., Scagnol, I., Rorive, A., Barbeaux, A., Coucke, P., & Jerusalem, G. (March 2010). Le cancer du sein "triple négatif". Revue Médicale de Liège, 65 (3), 120-126. Peer reviewed |
 | Coucke, P., Vavassis, P., Vanderick, J., & Jerusalem, G. (07 January 2010). Het belang van de tumormarge na conservatieve chirurgie bij borstkanker in een vroeg stadium. Nederlandsch Tijdschrift voor Verloskunde en Gynaecologie, 6, 227-235. Peer Reviewed verified by ORBi |
 | Di Leo, A., Jerusalem, G., Petruzelka, L., Torres, R., Bondarenko, I. N., Khasanov, R., Verhoeven, D., Pedrini, J. L., Smirnova, I., Lichinitser, M. R., Pendergrass, K., Garnett, S., Lindemann, J. P. O., Sapunar, F., & Martin, M. (2010). Results of the CONFIRM phase III trial comparing fulvestrant 250 mg with fulvestrant 500 mg in postmenopausal women with estrogen receptor-positive advanced breast cancer. Journal of Clinical Oncology, 28 (30), 4594-600. doi:10.1200/JCO.2010.28.8415 Peer Reviewed verified by ORBi |
 | Gennigens, C., Sautois, B., & Jerusalem, G. (2010). Le medicament du mois. Everolimus (RAD001/Afinitor) dans le traitement du cancer du rein métastatique. Revue Médicale de Liège, 65 (4), 212-6. Peer reviewed |
 | Bleret, V., Collignon, J., Coucke, P., Cusumano, G., DESREUX, J., Herman, P., Jerusalem, G., Maweja, S., Remacle, N., Rorive, A., & Lifrange, E. (2010). L'observance au traitement de longue durée : le cas particulier de l'hormonothérapie adjuvante du cancer du sein. Revue Médicale de Liège, 65 (5-6), 405-408. Peer reviewed |
 | JERUSALEM, G., Fasolo, A., Massacesi, C., Balaisius, M., Manlius, C., Sahmoud, T., Andre, F., & Gianni, L. (2010). Maintenance With Everolimus (RAD001) and Trastuzumab After Discontinuation of Chemotherapy in Heavily Pretreated HER-2+Metastatic Breast Cancer Patients: Pooled Data of Extension Cohorts of Phase Ib/II Studies. Journal of Clinical Oncology, 28 (15s), 1041. Peer Reviewed verified by ORBi |
 | Capri, G., Chang, J., Chen, S. C., Conte, P., Cwiertka, K., Jerusalem, G., Jiang, Z., Johnston, S., Kaufman, B., Link, J., Ro, J., Schutte, J., Oliva, C., Parikh, R., Preston, A., Rosenlund, J., Selzer, M., Zembryki, D., & De Placido, S. (2010). An open-label expanded access study of lapatinib and capecitabine in patients with HER2-overexpressing locally advanced or metastatic breast cancer. Annals of Oncology, 21 (3), 474-80. doi:10.1093/annonc/mdp373 Peer Reviewed verified by ORBi |
 | Coucke, P., Jansen, N., Collignon, J., Janvary, Z. L., Rorive, A., Vanderick, J., & Jerusalem, G. (January 2010). Pourquoi les traitements de radiothérapie adjuvante pour cancer du sein ne comptent-ils plus autant de séances ? Revue Médicale de Liège, 65 (1), 10-14. Peer reviewed |
 | Coudert, B., Campone, M., Spielmann, M., Symann, M., Eichler, F., Serin, D., Delozier, T., Romieu, G., Canon, J.-L., Orfeuvre, H., Piot, G., Petit, T., Chollet, P., JERUSALEM, G., Audhuy, B., Veyret, C., Beauduin, M., Eymard, J.-C., Martin, A.-L., & Roché, H. (15 December 2009). Benefit of the sequential administration of Docetaxel after standard FEC regimen for node-positive breast cancer : long-term follow-up results of the FNCLCC-PACS 01 trial. Cancer Research, 69. Peer Reviewed verified by ORBi |
 | Collignon, J., Gennigens, C., Rorive, A., Coucke, P., Lifrange, E., Maweja, S., Fillet, G., & Jerusalem, G. (May 2009). ANTICORPS MONOCLONAUX ET CANCER DU SEIN: Actualités thérapeutiques. Revue Médicale de Liège, 64 (5-6), 279-83. Peer reviewed |
 | Jerusalem, G., & Withofs, N. (2009). Nuclear medicine imaging. In H.-J. Schmoll, L. Van't Veer, J. Vermorken, ... D. Schrijvers (Eds.), ESMO Handbook of Cancer Diagnosis and Treatment Evaluation (pp. 29-36). Informa Healthcare. |
 | Gennigens, C., Kridelka, F., Jerusalem, G., & Sautois, B. (2009). Ovariumkanker : nieuwe cytotoxica en ontwikkeling van gerichte therapieën. Gunaïkeia. Koninklijke Belgische Vereniging voor Gynecologie en Verloskunde, 14 (6), 174-190. Peer reviewed |
 | Gennigens, C., Collignon, J., Jerusalem, G., Rorive, A., & Sautois, B. (2009). Anticorps monoclonaux a usage therapeutique en hemato-oncologie. Generalites. Revue Médicale de Liège, 64 (5-6), 264-7. Peer reviewed |
 | Coucke, P., Vavassis, P., Vanderick, J., & Jerusalem, G. (2009). Tumor Margin after conservative breast cancer surgery for early disease: an issue or not ? Belgian Journal of Medical Oncology, 3 (3), 93-100. Peer Reviewed verified by ORBi |
 | Mievis, C., Jansen, N., Schleich, F., Gennigens, C., Rorive, A., Jerusalem, G., Fillet, G., & Sautois, B. (2009). Le cas clinique du mois. Reaction de rappel d'irradiation induite par l'administration de cyclophosphamide. Revue Médicale de Liège, 64 (4), 179-81. Peer reviewed |
 | Van Vlaenderen, I., Canon, J. L., Cocquyt, V., Jerusalem, G., Machiels, J. P., Neven, P., Nechelput, M., Delabaye, I., Gyldmark, M., & Annemans, L. (2009). Trastuzumab treatment of early stage breast cancer is cost-effective from the perspective of the Belgian health care authorities. Acta Clinica Belgica, 64 (2), 100-12. Peer Reviewed verified by ORBi |
 | GONNE, E., Collignon, J., Kurth, W., Thiry, A., Henry, F., Jerusalem, G., & Gennigens, C. (2009). Angiosarcome sur lymphoedeme chronique: un cas de syndrome de Stewart-Treves. Revue Médicale de Liège, 64 (7-8), 409-13. Peer reviewed |
 | Coucke, P., Barthelemy, N., Jansen, N., Trivière, N., & Jerusalem, G. (February 2008). Carcinome intracanalaire (in situ) du sein : pouvons-nous raisonnablement éviter la radiothérapie pour certaines patientes opérées ? Revue Médicale de Liège, 63 (2), 75-81. Peer reviewed |
 | Hustinx, R., Jerusalem, G., & De Prijck, B. (2008). Tomographie à émission de positons et lymphomes. Médecine Nucléaire: Imagerie Fonctionnelle et Métabolique, 32, 449-455. doi:10.1016/j.mednuc.2008.06.002 Peer reviewed |
 | Coucke, P., Barthelemy, N., Jansen, N. (Other coll.), Triviere, N. (Other coll.), & Jerusalem, G. (Other coll.). (2008). Carcinome intracanalaire (in situ) du sein : pouvons-nous raisonnablement éviter les radiothérapie pour certaines patientes opérées? Revue Médicale de Liège, 63 (2), 75-81. Peer reviewed |
 | WITHOFS, N., GRAYET, B., Tancredi, T., RORIVE, A., BECKERS, C., JERUSALEM, G., & HUSTINX, R. (2008). PET/CT for assessing bone involvement in prostate and breast cancer. Journal of Nuclear Medicine, 49 (SUPPL), 21. Peer Reviewed verified by ORBi |
 | Gennigens, C., Sautois, B., Rorive, A., Fillet, G., & Jerusalem, G. (2007). Actualites therapeutiques en oncologie: l'essor des therapeutiques ciblees. Revue Médicale de Liège, 62 (5-6, May-Jun), 391-8. Peer reviewed |
 | Giuliani, R., Durbecq, V., Di Leo, A., Paesmans, M., Larsimont, D., Leroy, J.-Y., Borms, M., Vindevoghel, A., Jerusalem, G., D'Hondt, V., Dirix, L., Canon, J.-L., Richard, V., Cocquyt, V., Majois, F., Reginster, M., Demol, J., Kains, J.-P., Delree, P., ... Cardoso, F. (2007). Phosphorylated HER-2 tyrosine kinase and Her-2/neu gene amplification as predictive factors of response to trastuzumab in patients with HER-2 overexpressing metastatic breast cancer (MBC). European Journal of Cancer, 43 (4), 725-35. doi:10.1016/j.ejca.2006.11.019 Peer Reviewed verified by ORBi |
 | Jerusalem, G., Withofs, N., Rorive, A., & Hustinx, R. (2007). Tomographie a emission de positons: un premier bilan. Revue du Praticien, 57 (17), 1864-70. Peer reviewed |
 | Jerusalem, G., Rorive, A., Gennigens, C., Sautois, B., Mievis, C., & Fillet, G. (2007). Actualités thérapeutiques en oncologie sénologique: place actuelle et perspectives des traitements cibles. Revue Médicale de Liège, 62 Spec No, 2-5. Peer reviewed |
 | Jerusalem, G., Silvestre, R., Beguin, Y., Hustinx, R., Fassotte, M.-F., & Fillet, G. (20 June 2006). FDG-PET for the routine follow-up in NHL: First prospective evaluation. Journal of Clinical Oncology, 24 (18, Part 1 Suppl. S), 439. Peer Reviewed verified by ORBi |
 | Jerusalem, G., & Beguin, Y. (2006). The place of positron emission tomography imaging in the management of patients with malignant lymphoma. Haematologica, 91 (4), 442-4. Peer Reviewed verified by ORBi |
 | Jerusalem, G., Rorive, A., Ancion, G., Hustinx, R., & Fillet, G. (2006). Diagnostic and therapeutic management of carcinoma of unknown primary: radio-imaging investigations. Annals of Oncology, 17 Suppl 10, 168-76. doi:10.1093/annonc/mdl255 Peer Reviewed verified by ORBi |
 | Jerusalem, G., Hustinx, R., & Rigo, P. (2006). PET and PET/CT imaging in lymphomas. In P. E. Valk, D. Delbeke, D. L. Bailey, D. W. Townsend, ... M. N. Maisey, Positron emission tomography (pp. 125-145). Londres, United Kingdom: Springer. |
 | Jerusalem, G., & Hustinx, R. (2006). The lymphomas. Nuclear Medicine. In G. P. Canellos, A. T. Lister, ... B. Young, The lymphomas (pp. 189-202). Philadelphia, United States: Saunders. |
 | Couturier, O., Jerusalem, G., N'Guyen, J.-M., & Hustinx, R. (2006). Sequential positron emission tomography using [18F]fluorodeoxyglucose for monitoring response to chemotherapy in metastatic breast cancer. Clinical Cancer Research, 12 (21), 6437-43. doi:10.1158/1078-0432.CCR-06-0383 Peer Reviewed verified by ORBi |
 | Jerusalem, G., Hustinx, R., Beguin, Y., & Fillet, G. (2005). Evaluation of therapy for lymphoma. Seminars in Nuclear Medicine, 35 (3), 186-96. doi:10.1053/j.semnuclmed.2005.02.004 Peer Reviewed verified by ORBi |
 | Depas, G., De Barsy, C., Jerusalem, G., Hoyoux, C., DRESSE, M.-F., Fassotte, M.-F., Paquet, N., Willems, J., Rigo, P., & Hustinx, R. (January 2005). F-18-FDG PET in children with lymphomas. European Journal of Nuclear Medicine and Molecular Imaging, 32 (1), 31-38. doi:10.1007/s00259-004-1604-z Peer Reviewed verified by ORBi |
 | Jerusalem, G., Hustinx, R., Beguin, Y., & Fillet, G. (2005). Whole-Body Positron Emission Tomography using 18F-Fluorodeoxyglucose for Staging Response Assessment in Hodgkin's Disease. In B. C. Heinz (Ed.), Trends in Hodgkin's Disease Research (pp. 169-188). New York, United States: Nova Science Publishers. |
 | Jerusalem, G., Hustinx, R., Beguin, Y., & Fillet, G. (2005). Positron emission tomography imaging for lymphoma. Current Opinion in Oncology, 17 (5), 441-5. doi:10.1097/01.cco.0000174041.29557.5c Peer Reviewed verified by ORBi |
 | Jerusalem, G., & Belhocine, T. Z. (2005). Metabolic monitoring of chemosensitivity with 18FDG PET. Methods in Molecular Medicine, 111, 417-40. doi:10.1385/1-59259-889-7:417 Peer Reviewed verified by ORBi |
 | Focan, C., Graas, M. P., Beauduin, M., Canon, J. L., Salmon, J.-P., Jerusalem, G., Focan-Henrard, D., Lobelle, J. P., & Schallier, D. (2005). Sequential administration of epirubicin and paclitaxel for advanced breast cancer. A phase I randomised trial. Anticancer Research, 25 (2B), 1211-7. Peer Reviewed verified by ORBi |
 | Polus, M., Piront, P., Jerusalem, G., Sautois, B., Defechereux, T., de Leval, L., & Fillet, G. (February 2004). L'image du mois. Tumeur de Merkel : reponse majeure a la chimiotherapie. "Il n'y a pas que la neige qui fond au soleil". Revue Médicale de Liège, 59 (2), 67-8. Peer reviewed |
 | Gillain, S., Gennigens, C., Sautois, B., Polus, M., Bonnet, C., Fillet, G., & Jerusalem, G. (2004). Traitement du cancer du sein chez la personne âgée. Revue Médicale Suisse, 62, 1618-21. Peer Reviewed verified by ORBi |
 | Baron, F., Copizza, S., Baudoux, E., Jerusalem, G., Fillet, G., & Beguin, Y. (2004). CD34+ cell dose predicts costs after autologous peripheral blood stem cell transplantation for breast cancer. Haematologica, 89 (9), 1146-8. Peer Reviewed verified by ORBi |
 | Jerusalem, G., & Hustinx, R. (15 October 2003). Tomographie a emission de positons: une revolution en cancerologie? Revue du Praticien, 53 (15), 1629-30. Peer reviewed |
 | Polus, M., Piront, P., Jerusalem, G., Sautois, B., Louis, E., Detroz, B., Laurent, S., Belaiche, J., & Fillet, G. (April 2003). Prevention primaire et secondaire du cancer colorectal. Revue Médicale de Liège, 58 (4), 247-53. Peer reviewed |
 | Hustinx, R., Lemaire, C., Jerusalem, G., Moreau, P., Cataldo, D., Duysinx, B., Aerts, J., Fassotte, M.-F., Foidart, J., & Luxen, A. (April 2003). Whole-body tumor imaging using PET and 2-18F-fluoro-l-tyrosine: Preliminary evaluation and comparison with 18F-FDG. Journal of Nuclear Medicine, 44 (4), 533-539. Peer Reviewed verified by ORBi |
 | Jerusalem, G., Beguin, Y., Fassotte, M.-F., Belhocine, T., Hustinx, R., Rigo, P., & Fillet, G. (2003). Early detection of relapse by whole-body positron emission tomography in the follow-up of patients with Hodgkin's disease. Annals of Oncology, 14 (1), 123-30. doi:10.1093/annonc/mdg011 Peer Reviewed verified by ORBi |
 | Jerusalem, G., Hustinx, R., Beguin, Y., Depas, G., Fassotte, M.-F., De Barsy, C., Foidart, J., & Fillet, G. (2003). Les lymphomes. Médecine Nucléaire: Imagerie Fonctionnelle et Métabolique, 27 (8), 401-410. Peer reviewed |
 | Andre, M., Baudoux, E., Bron, D., Canon, J.-L., D'Hondt, V., Fassotte, M.-F., D'Hondt, L., Fillet, G., Humblet, Y., Jerusalem, G., Vermeulen, P., Symann, M., & Beguin, Y. (2003). Phase III randomized study comparing 5 or 10 microg per kg per day of filgrastim for mobilization of peripheral blood progenitor cells with chemotherapy, followed by intensification and autologous transplantation in patients with nonmyeloid malignancies. Transfusion, 43 (1), 50-7. doi:10.1046/j.1537-2995.2003.00273.x Peer Reviewed verified by ORBi |
 | Jerusalem, G., Hustinx, R., Beguin, Y., & Fillet, G. (2003). PET scan imaging in oncology. European Journal of Cancer, 39 (11), 1525-34. doi:10.1016/S0959-8049(03)00374-5 Peer Reviewed verified by ORBi |
 | DE BARSY, DEPAS, G., DRESSE, M.-F., HOYOUX, C., SCHMITZ, V., JERUSALEM, G., FASSOTTE, M.-F., FOIDART-WILLEMS, J., & HUSTINX, R. (2003). Whole-body FDG PET imaging as a method for staging and early assessment of treatment response in pediatric patients with lymphoma. Journal of Nuclear Medicine, 44, 183. Peer Reviewed verified by ORBi |
 | Hustinx, R., Sautois, B., Jerusalem, G., & Foidart, J. (2003). Radiothérapie métabolique des douleurs osseuses métastatiques. Médecine et Hygiène, 61, 1560-1564. Peer Reviewed verified by ORBi |
 | DE BARSY, DEPAS, G., DRESSE, M.-F., HOYOUX, C., SCHMITZ, V., JERUSALEM, G., FASSOTTE, M.-F., FOIDART-WILLEMS, J., & HUSTINX, R. (2003). Whole-body FDG PET in the follow-up of pediatric patients with lymphoma. Journal of Nuclear Medicine, 44, 346. Peer Reviewed verified by ORBi |
Jerusalem, G., Rigo, P., & Israel, O. (2003). PET and PET/CT of lymphoma. In G. K. von Schulthess (Ed.), Clinical Molecular Anatomic Imaging (pp. 350-361). Lippincott Williams and Wilkins. |
Jerusalem, G., & Rigo, P. (2003). PET Imaging in Lymphoma. In P. E. Valk, D. L. Bailey, D. W. Townsend, ... M. N. Maisey (Eds.), Positron emission tomography (pp. 547-557). Springer. |
 | Pelerin, D., Silvestre, R. M., Jerusalem, G., Sautois, B., Polus, M., & Fillet, G. (December 2002). Comment je traite ... par hormonotherapie des patientes developpant des complications thrombo-emboliques lors du traitement d'un cancer du sein par tamoxifene. Revue Médicale de Liège, 57 (12), 755-6. Peer reviewed |
 | Polus, M., Honore, P., De Roover, A., Detry, O., Detroz, B., Jerusalem, G., Sautois, B., & Fillet, G. (December 2002). La carcinomatose hepatique du cancer colorectal: actualites therapeutiques. Revue Médicale de Liège, 57 (12), 771-8. Peer reviewed |
 | Belhocine, T., Steinmetz, N., Hustinx, R., Bartsch, P., Jerusalem, G., Seidel, L., Rigo, P., & Green, A. (September 2002). Increased uptake of the apoptosis-imaging agent (99m)Tc recombinant human annexin V in human tumors after one course of chemotherapy as a predictor of tumor response and patient prognosis. Clinical Cancer Research, 8 (9), 2766-2774. Peer Reviewed verified by ORBi |
 | Polus, M., Bours, V., Jerusalem, G., Sautois, B., & Fillet, G. (July 2002). Comment je traite.... Le cancer avance du pancreas par une approche innovante dirigee contre les nouvelles cibles. Revue Médicale de Liège, 57 (7), 428-32. Peer reviewed |
 | Polus, M., Jerusalem, G., Sautois, B., Silvestre, R. M., & Fillet, G. (March 2002). Comment je traite.... Un cancer du pancreas avance. Revue Médicale de Liège, 57 (3), 131-4. Peer reviewed |
 | Polus, M., Jerusalem, G., Sautois, B., Silvestre, R. M., Collette, M. Y., Closon, M. T., & Fillet, G. (February 2002). Etude clinique du mois. Radio-chimiotherapie et chimiotherapie adjuvante apres resection a visee curative du cancer du pancreas: resultats de l'etude randomisee ESPAC-1. Revue Médicale de Liège, 57 (2), 119-22. Peer reviewed |
 | Jerusalem, G., & Beguin, Y. (2002). Does positron emission tomography have a role in routine clinical practice in patients with Hodgkin's disease? Clinical Lymphoma, 3 (2), 125-6. doi:10.1016/S1526-9655(11)70258-5 Peer Reviewed verified by ORBi |
 | Jerusalem, G., Hustinx, R., Beguin, Y., & Fillet, G. (2002). The value of positron emission tomography (PET) imaging in disease staging and therapy assessment. Annals of Oncology, 13 Suppl 4, 227-34. doi:10.1093/annonc/mdf664 Peer Reviewed verified by ORBi |
 | Jerusalem, G., & Beguin, Y. (2002). Commentary on "Noninvasive detection of multidrug resistance in patients with hematological malignancies: are we there yet?". Clinical Lymphoma, 2 (4), 249. doi:10.1016/S1526-9655(11)70232-9 Peer Reviewed verified by ORBi |
 | Warland, V., Jerusalem, G., Hustinx, R., Beguin, Y., Silvestre, R. M., Fassotte, M.-F., Foidart, J., & Fillet, G. (2002). Comment etablir le bilan de fin de traitement des patients atteints de lymphomes non-hodgkiniens (LNH) de malignite intermediaire ou elevee? Revue Médicale de Liège, 57 (12), 779-84. Peer reviewed |
 | Jerusalem, G., & Beguin, Y. (2002). Positron emission tomography in non-Hodgkin's lymphoma (NHL): relationship between tracer uptake and pathological findings, including preliminary experience in the staging of low-grade NHL. Clinical Lymphoma, 3 (1), 56-61. doi:10.3816/CLM.2002.n.012 Peer Reviewed verified by ORBi |
 | HUSTINX, R., Lemaire, C., JERUSALEM, G., MOREAU, P., Cataldo, D., DUYSINX, B., Aerts, J., & Luxen, A. (2002). 18F-fluoro-L-tyrosine : a potential tracer for whole-body tumor imaging with PET. Journal of Nuclear Medicine, 43, 77. Peer Reviewed verified by ORBi |
 | Brasseur, E., Silvestre, R.-M., Jerusalem, G., Sautois, B., Polus, M., & Fillet, G. (2002). Prévention et traitement des nausées et vomissements après chimiothérapie anticancéreuse. Médecine et Hygiène, 60, 1509-1513. Peer Reviewed verified by ORBi |
 | Najjar, F., Hustinx, R., Jerusalem, G., Fillet, G., & Rigo, P. (August 2001). Positron Emission Tomography (PET) for Staging Low-Grade Non-Hodgkin's Lymphomas (NHL). Cancer Biotherapy and Radiopharmaceuticals, 16 (4), 297-304. doi:10.1089/108497801753131372 Peer Reviewed verified by ORBi |
 | Sylvestre, R.-M., Jerusalem, G., Sautois, B., Beguin, Y., & Fillet, G. (2001). Nouvelles approches thérapeutiques puor l'hypernéphrome métastasique. Médecine et Hygiène, 59, 1607-1609. Peer Reviewed verified by ORBi |
 | Jerusalem, G., Beguin, Y., Najjar, F., Hustinx, R., Fassotte, M.-F., Rigo, P., & Fillet, G. (2001). Positron emission tomography (PET) with 18F-fluorodeoxyglucose (18F-FDG) for the staging of low-grade non-Hodgkin's lymphoma (NHL). Annals of Oncology, 12 (6), 825-30. doi:10.1023/A:1011169332265 Peer Reviewed verified by ORBi |
 | Jerusalem, G., Belhocine, T., Silvestre, R.-M., Sautois, B., Hustinx, R., Beguin, Y., Fillet, G., & Rigo, P. (2001). Place de la tomographie d'émission de positons dans le suivi thérapeutique du cancer du sein. Médecine Nucléaire: Imagerie Fonctionnelle et Métabolique, 25 (6), 341-346. Peer reviewed |
 | Jerusalem, G., Beguin, Y., Fassotte, M.-F., Najjar, F., Paulus, P., Rigo, P., & Fillet, G. (2001). Whole-body positron emission tomography using 18F-fluorodeoxyglucose compared to standard procedures for staging patients with Hodgkin's disease. Haematologica, 86 (3), 266-73. Peer Reviewed verified by ORBi |
 | JERUSALEM, G., & BEGUIN, Y. (June 2000). Commentary on "Positron emission tomography in lymphoma : comparison with computed tomography and Gallium-67 single photon emission computed tomography imaging". Clinical Lymphoma, 1 (1), 75-76. Peer Reviewed verified by ORBi |
Jerusalem, G., Bours, V., & Fillet, G. (May 2000). Traitement adjuvant du cancer du sein: meta-analyse et recommandations therapeutiques. Revue Médicale de Liège, 55 (5), 356-9. Peer reviewed |
Jerusalem, G., Bours, V., & Fillet, G. (March 2000). Existe-t-il des progres dans le traitement du cancer du pancreas metastatique? Revue Médicale de Liège, 55 (3), 146-8. Peer reviewed |
 | BELHOCINE, T., HUSTINX, R., JERUSALEM, G., FASSOTTE, M.-F., DUYSINX, B., QUADEN, C., & RIGO, P. (2000). 99mTc rh-Annexin V (ApomateTM) as a marker of apoptosis resulting from chemotherapy : preliminary results. Journal of Nuclear Medicine, 41 (SUPPL), 263. Peer Reviewed verified by ORBi |
 | Bonnet, C., Jerusalem, G., Bours, V., & Fillet, G. (2000). Approches thérapeutiques du cancer ovarien. Médecine et Hygiène, 58, 1625-1628. Peer Reviewed verified by ORBi |
 | Fraipont, V., Sautois, B., Baudoux, E., Pereira-Martins, M., Fassotte, M.-F., Hermanne, J. P., Jerusalem, G., Longree, L., Schaaf-Lafontaine, N., Fillet, G., & Beguin, Y. (2000). Successful mobilization of peripheral blood HPCs with G-CSF alone in patients failing to achieve sufficient numbers of CD34+ cells and/or CFU-GM with chemotherapy and G-CSF. Transfusion, 40 (3), 339-47. doi:10.1046/j.1537-2995.2000.40030339.x Peer Reviewed verified by ORBi |
 | Jerusalem, G., Beguin, Y., Fassotte, M.-F., Najjar, F., Paulus, P., Rigo, P., & Fillet, G. (2000). Persistent tumor 18F-FDG uptake after a few cycles of polychemotherapy is predictive of treatment failure in non-Hodgkin's lymphoma. Haematologica, 85 (6), 613-8. Peer Reviewed verified by ORBi |
 | Jerusalem, G., Beguin, Y., Fassotte, M.-F., Belhocine, T., Najjar, F., Hustinx, R., Rigo, P., & Fillet, G. (2000). Evaluation thérapeutique précoce par tomographie à émission de positons. Médecine et Hygiène, 58, 1629-1632. Peer Reviewed verified by ORBi |
 | JERUSALEM, G., BEGUIN, Y., FASSOTTE, M.-F., BELHOCINE, T., HUSTINX, R., RIGO, P., & FILLET, G. (2000). Early detection of relapse by whole-body positron emission tomography (PET) using 18F-fluorodeoxyglucose (18F-FDG) in the follow-up of patients with Hodgkin’s disease (HD). PROCEEDINGS OF AMERICAN SOCIETY OF CLINICAL ONCOLOGY ANNUAL MEETING 2000, 19, 10. Peer reviewed |
 | NAJJAR, F., HUSTINX, R., JERUSALEM, G., FILLET, G., & RIGO, P. (2000). Whole-body 18FDG-PET for staging low grade non Hodgkin’s lymphoma. European Journal of Nuclear Medicine, 27, 1159. Peer Reviewed verified by ORBi |
Jerusalem, G., & Beguin, Y. (2000). Clinical impact and perspectives of 18F-FDG PET in lymphoma. Clinical Lymphoma, 1, 75-76. Peer Reviewed verified by ORBi |
Jerusalem, G. (1999). Place de la tomographie à émission de positons au 18F-FDG dans le bilan d'extension, l'évaluation thérapeutique précoce et le suivi des patients atteints de lymphomes hodgkiniens et non-hodgkiniens [Doctoral thesis, ULiège - Université de Liège]. ORBi-University of Liège. https://orbi.uliege.be/handle/2268/76158 |
 | Sautois, B., Fraipont, V., Baudoux, E., Fassotte, M.-F., Hermanne, J. P., Jerusalem, G., Bours, V., Bosquee, L., Schaaf-Lafontaine, N., Paulus, J.-M., Sondag, D., Fillet, G., & Beguin, Y. (1999). Peripheral blood progenitor cell collections in cancer patients: analysis of factors affecting the yields. Haematologica, 84 (4), 342-9. Peer Reviewed verified by ORBi |
 | Najjar, F., Jerusalem, G., Paulus, P., Fillet, G., & Rigo, P. (1999). Intérêt clinique de la tomographie à émission de positons dans la détection et le bilan d'extension des lymphomes non Hodgkiniens de malignité intermédiaire ou élevée. Médecine Nucléaire: Imagerie Fonctionnelle et Métabolique, 23, 281-290. Peer reviewed |
Rezaei Kalantari, H., Jerusalem, G., Bours, V., & Fillet, G. (January 1999). Les tumeurs malignes d'origine indéterminée. Revue Médicale de Liège, 54 (1), 39-42. Peer reviewed |
 | Jerusalem, G., Beguin, Y., Fassotte, M.-F., Najjar, F., Paulus, P., Rigo, P., & Fillet, G. (1999). Whole-body positron emission tomography using 18F-fluorodeoxyglucose for posttreatment evaluation in Hodgkin's disease and non-Hodgkin's lymphoma has higher diagnostic and prognostic value than classical computed tomography scan imaging. Blood, 94 (2), 429-33. doi:10.1182/blood.v94.2.429.414k26_429_433 Peer Reviewed verified by ORBi |
 | Jerusalem, G., Bours, V., & Fillet, G. (1999). Actualités thérapeutiques dans le traitement du cancer colorectal. Médecine et Hygiène, 57, 1552-1554. Peer Reviewed verified by ORBi |
 | Jerusalem, G., Warland, V., Najjar, F., Paulus, P., Fassotte, M. F., Fillet, G., & Rigo, P. (January 1999). Whole-Body 18f-Fdg Pet for the Evaluation of Patients with Hodgkin's Disease and Non-Hodgkin's Lymphoma. Nuclear Medicine Communications, 20 (1), 13-20. doi:10.1097/00006231-199901000-00004 Peer Reviewed verified by ORBi |
Jerusalem, G., Bours, V., & Fillet, G. (June 1998). Pharma-clinics. Comment je traite... II. Approche thérapeutique du cancer colorectal métastatique. Revue Médicale de Liège, 53 (6), 318-21. Peer reviewed |
Jerusalem, G., Bours, V., & Fillet, G. (May 1998). Traitement du cancer colorectal. Aspects pharmaco-économiques. Revue Médicale de Liège, 53 (5), 276-8. Peer reviewed |
Bours, V., Jerusalem, G., & Fillet, G. (April 1998). Comment je traite ... Le cancer colorectal: I. Prévention et traitement adjuvant. Revue Médicale de Liège, 53 (4), 167-70. Peer reviewed |
 | Hustinx, R., Paulus, P., Jacquet, N., Jerusalem, G., Bury, T., & Rigo, P. (1998). Clinical evaluation of whole-body 18F-fluorodeoxyglucose positron emission tomography in the detection of liver metastases. Annals of Oncology, 9 (4), 397-401. doi:10.1023/A:1008290027419 Peer Reviewed verified by ORBi |
 | Pierard, G., Nikkels, N., Nikkels, A., Arrese Estrada, J., Pierard, C., Jerusalem, G., Beguin, Y., & Fillet, G. (1998). Epidermal Calprotectin Expression in Lymphocyte-Depleted Cutaneous Graft-versus-Host Reaction. Archivos Argentinos de Dermatologia, 48, 139-142. Peer Reviewed verified by ORBi |
Jerusalem, G., & Fillet, G. (April 1997). Problèmes diagnostiques, thérapeutiques et socio-économiques en oncologie gériatrique. Revue Médicale de Liège, 52 (4), 255-7. Peer reviewed |
 | Rigo, P., Paulus, P., Bury, T., Jerusalem, G., Hustinx, R., Benoit, T., Larock, M.-P., & Foidart, J. (1997). Clinical PET in oncology. Radioactive Isotopes in Clinical Medicine Research XXII. Peer reviewed |
 | Jerusalem, G., & Fillet, G. (1997). Les taxanes : un nouvelle classe d'agents cytotoxiques. Médecine et Hygiène, 55, 1501-1504. Peer Reviewed verified by ORBi |
 | Rigo, P., Paulus, P., Bury, T., Jerusalem, G., Hustinx, R., Benoit, T., Larock, M.-P., & Willems, J. (1997). Clinical PET in Oncology. In H. Bergmann, A. Kroiss, ... Sinzinger H (Eds.), Radioactive Isotopes in Clinical Medicine and Research (pp. 3-14). Basel, Switzerland: Birhauser Verlag. |
Jerusalem, G. (1997). Actualisation du traitement des cancers du sein. Chimiothérapie myéloblastique et greffes de cellules souches hématopoiétiques. Revue Médicale de Liège, 52 (2), 76-9. Peer reviewed |
 | Rigo, P., Paulus, P., Kaschten, B., Hustinx, R., Bury, T., Jerusalem, G., Benoit, T., & Foidart-Willems, J. (December 1996). Oncological Applications of Positron Emission Tomography with Fluorine-18 Fluorodeoxyglucose. European Journal of Nuclear Medicine, 23 (12), 1641-74. doi:10.1007/BF01249629 Peer Reviewed verified by ORBi |
 | HUSTINX, R., PAULUS, P., DAENEN, F., JERUSALEM, G., JACQUET, N., & RIGO, P. (May 1996). PET imaging of liver metastases: a retrospective study. Journal of Nuclear Medicine, 37, 250P-251. Peer Reviewed verified by ORBi |
 | HUSTINX, R., PAULUS, P., BENOIT, T., JERUSALEM, G., JACQUET, N., & RIGO, P. (1996). Clinical value of whole body-body PET-FDG in the detection of liver metastases: preliminary results. European Journal of Nuclear Medicine, 23, 1110. Peer Reviewed verified by ORBi |
 | Rigo, P., Paulus, P., JERUSALEM, G., BURY, T., Deneufbourg, J.-M., Depas, G., Benoît, T., Larock, M.-P., & Foidart, J. (1995). Indications cliniques de la tomographie à positons au 18FDG en oncologie. Expérience préliminaire et revue de la littérature. Médecine Nucléaire: Imagerie Fonctionnelle et Métabolique, 19, 73-89. Peer reviewed |
 | Jerusalem, G., Detroz, B., Herman, P., Dohogne, A., Closon, M. T., Jacquet, N., Honoré, P., Bruyninx, L., Fillet, G., Fassotte, M.-F., Bours, V., & Lipcsei, G. (1995). Approche thérapeutique du cancer épithélial de l'ovaire au CHU Sart Tilman : Conclusions de la réunion interdisciplinaire du 22 mars 1995. Revue Médicale de Liège, 50, 469-471. Peer reviewed |
